> l \pThe Free Software Foundation B=PF0*8X@"1 Helvetica1Courier1Courier New1Courier New1 Helvetica$#,##0_);($#,##0)$#,##0_);[Red]($#,##0)$#,##0.00_);($#,##0.00)$#,##0.00_);[Red]($#,##0.00)**_($* #,##0_);_($* (#,##0);_($* ""_);_(@_)*)'_(* #,##0_);_(* (#,##0);_(* ""_);_(@_)5,2_($* #,##0.00_);_($* (#,##0.00);_($* ""??_);_(@_)2+/_(* #,##0.00_);_(* (#,##0.00);_(* ""??_);_(@_)2$#,##0.00;[Red]$#,##0.003$#,##0.00;[Red]($#,##0.00)4$#,##0;[Red]($#,##00)50.00%;[Red](0.00%)60%;[Red](0%)7#,##0.00;[Red](#,##0.00)8#,##0;[Red](#,##0) + ) , * Ј ~~ ؈ ~~#؈ ~~"؈ ~~ ؈ ~~8#܈ ~~<#܈ ~~4#܈ ~~3#܈ ~~7#܈ ~~"؈ ~~83ffff̙̙3f3fff3f3f33333f33
Boston MA 02116k
Balance Sheet/Balance Sheet (1)PIncome StatementBr
Cash Flows,Balance Sheet (2)&3 Cash and Cash Equivalents and7 5 Fixed Assetsy6 Intangible Assets Net&e7 Net Loss Per Share Available &Warrants to Purchase Common Sto $10 Other Accrued Expenses!511 Fair Value MeasurementsContingent Consideration!w#12 StockBased Compensation9212 StockBased C (1)?
Stock options U16 Restricted Stock Unitsd13 Longterm Debt
pLeases&}Research and Development Expens&Comparison of the three months &Comparison of the nine months e&Liquidity and Capital Resourcesi34 EXHIBIT INDEX434 EXHIBIT INDE (1)
35 36 SIGNATURES&Remainder of this page is inten&&138 Entire Agreement The obliga5Prior Inventions&OA2Due to a prior confidentiality%NRemainder of this page is (1)$2[138 Entire Agreement The (1)iPrior Invention (1)Iu2Due to a prior (1)%Remainder of this page is (2)$138 Entire Agreement The (2)Prior Invention (2)2Due to a prior (2)%Remainder of this page is (3)$3138 Entire Agreement The (3)Prior Invention (3)2Due to a prior (3)%Remainder of this page is (4)$u138 Entire Agreement The (4) Prior Invention (4)2Due to a prior (4)&!SECTION 302 OF THE SARBANESOXLE,SECTION 302 OF THE (1)&u7SECTION 906 OF THE SARBANESOXLEASECTION 906 OF THE (1)
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??2
Balance SheetBalance Sheet (1)Income Statement
Cash FlowsBalance Sheet (2)!3 Cash and Cash Equivalents and7 5 Fixed Assets6 Intangible Assets Net!7 Net Loss Per Share Available !Warrants to Purchase Common Sto10 Other Accrued Expenses11 Fair Value MeasurementsContingent Consideration12 StockBased Compensation12 StockBased C (1)
Stock options16 Restricted Stock Units13 Longterm DebtLeases!Research and Development Expens!Comparison of the three months !Comparison of the nine months e!Liquidity and Capital Resources34 EXHIBIT INDEX34 EXHIBIT INDE (1)35 36 SIGNATURES!Remainder of this page is inten!138 Entire Agreement The obligaPrior Inventions!2Due to a prior confidentiality Remainder of this page is (1)138 Entire Agreement The (1)Prior Invention (1)2Due to a prior (1) Remainder of this page is (2)138 Entire Agreement The (2)Prior Invention (2)2Due to a prior (2) Remainder of this page is (3)138 Entire Agreement The (3)Prior Invention (3)2Due to a prior (3) Remainder of this page is (4)138 Entire Agreement The (4)Prior Invention (4)2Due to a prior (4)!SECTION 302 OF THE SARBANESOXLESECTION 302 OF THE (1)!SECTION 906 OF THE SARBANESOXLESECTION 906 OF THE (1)U }U}8}}$
%Paratek Pharmaceuticals, Inc.10Q
11/08/2017Boston, MA 02116Large accelerated filer ?Accelerated filer ?
Nonaccelerated filer7
/? (Do not check if a smaller reporting company)!
Smaller reporting company
?Emerging growth company ?
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/&@}qeM=PF0*8X>
@
l 4K)@/
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??2Boston MA 02116Balance Sheet (1)Income Statement
Cash FlowsBalance Sheet (2)!3 Cash and Cash Equivalents and7 5 Fixed Assets6 Intangible Assets Net!7 Net Loss Per Share Available !Warrants to Purchase Common Sto10 Other Accrued Expenses11 Fair Value MeasurementsContingent Consideration12 StockBased Compensation12 StockBased C (1)
Stock options16 Restricted Stock Units13 Longterm DebtLeases!Research and Development Expens!Comparison of the three months !Comparison of the nine months e!Liquidity and Capital Resources34 EXHIBIT INDEX34 EXHIBIT INDE (1)35 36 SIGNATURES!Remainder of this page is inten!138 Entire Agreement The obligaPrior Inventions!2Due to a prior confidentiality Remainder of this page is (1)138 Entire Agreement The (1)Prior Invention (1)2Due to a prior (1) Remainder of this page is (2)138 Entire Agreement The (2)Prior Invention (2)2Due to a prior (2) Remainder of this page is (3)138 Entire Agreement The (3)Prior Invention (3)2Due to a prior (3) Remainder of this page is (4)138 Entire Agreement The (4)Prior Invention (4)2Due to a prior (4)!SECTION 302 OF THE SARBANESOXLESECTION 302 OF THE (1)!SECTION 906 OF THE SARBANESOXLESECTION 906 OF THE (1)U }y
}:}$ }
4
%Paratek Pharmaceuticals, Inc.10Q
11/08/2017
Balance SheetPage$ PART I FINANCIAL INFORMATION
Item 1.( Financial Statements (unaudited)~

%Condensed Consolidated Balance Sheets
~
1)as of September 30, 2017 and December 31,~
,$Condensed Consolidated Statements of~
%Operations and Comprehensive Loss for1)the Three and Nine Months Ended September30, 2017 and 2016,$Condensed Consolidated Statements of~
6.Cash Flows for the Nine Months Ended September30, 2017 and 20161)Notes to Unaudited Condensed Consolidated~
Financial StatementsItem 2.,$Management?s Discussion and Analysis~
^80of Financial Condition and Results of OperationsDlth4k;Y\,g7# !"#$%&'()*+,./0123 Item 3.0 (Quantitative and Qualitative Disclosures ~
!!About Market Risk""""#Item 4.#Controls and Procedures#~
#$$$$!%PART II OTHER INFORMATION%%&&&&'Item 1.'Legal Proceedings'~
'(((()Item 1A.)Risk Factors)~
)****+Item 6.+Exhibits+~
+,,,,
SIGNATURES~
..../0$1____________________________12)Created by Morningstar Document Research.03(http://documentresearch.morningstar.com/,vFYi(tL=PF0*8X>
@*332211%%
l 7EP
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??2Boston MA 02116
Balance SheetIncome Statement
Cash FlowsBalance Sheet (2)!3 Cash and Cash Equivalents and7 5 Fixed Assets6 Intangible Assets Net!7 Net Loss Per Share Available !Warrants to Purchase Common Sto10 Other Accrued Expenses11 Fair Value MeasurementsContingent Consideration12 StockBased Compensation12 StockBased C (1)
Stock options16 Restricted Stock Units13 Longterm DebtLeases!Research and Development Expens!Comparison of the three months !Comparison of the nine months e!Liquidity and Capital Resources34 EXHIBIT INDEX34 EXHIBIT INDE (1)35 36 SIGNATURES!Remainder of this page is inten!138 Entire Agreement The obligaPrior Inventions!2Due to a prior confidentiality Remainder of this page is (1)138 Entire Agreement The (1)Prior Invention (1)2Due to a prior (1) Remainder of this page is (2)138 Entire Agreement The (2)Prior Invention (2)2Due to a prior (2) Remainder of this page is (3)138 Entire Agreement The (3)Prior Invention (3)2Due to a prior (3) Remainder of this page is (4)138 Entire Agreement The (4)Prior Invention (4)2Due to a prior (4)!SECTION 302 OF THE SARBANESOXLESECTION 302 OF THE (1)!SECTION 906 OF THE SARBANESOXLESECTION 906 OF THE (1)U }U5}$ }
}$ }}$
7
%Paratek Pharmaceuticals, Inc.10Q
11/08/2017
Balance Sheet
September 30,December 31, ~
~
Assets
Current assets!Cash and cash equivalents~
~
;%
Availableforsale securities
~
6
~
Restricted cash~
~
Other receivable ?~
( Prepaid and other current assets~
(~
Total current assets~
$
~
Restricted cash~
~
Fixed assets, net~
~
Intangible assets, net~
~
Goodwill~
~
Other longterm assets~
~
zTotal assets~
\
~
H,$Liabilities and stockholders? equityCurrent liabilitiesAccounts payable~
,~
EOther accrued expenses~
R~
rd!Accrued contract research~
G~
z!Total current liabilities~
~
>Longterm debt~
~
`Contingent obligations~
R~
>
Dlth=RF74/;TE ! " # $ % & ' ( ) * + ,  . / 0 1 2 3 4 5 6 Other liabilities ~
L ~
@ !Total liabilities!!~
!C!!!~
!2!/"'Commitments and contingencies (Note 15)""""""""#Stockholders? equity########$Preferred stock:$$$$$$$$,%$Undesignated preferred stock, $0.001%% %?%%% %?%/&'par value; 5,000,000 shares authorized;+'# no shares issued and outstanding3(+Common stock, $0.001 par value; 100,000,000((~
(r(((~
(^())!shares authorized; 27,892,040 and3*+ 23,358,637 shares issued and outstanding4+,at September 30, 2017 and December 31, 2016,,respectively"Additional paidin capital~
t!~
,.$Accumulated other comprehensive loss..~
....~
../Accumulated deficit//~
////~
//"0Total stockholders? equity00~
0000~
0^021*Total liabilities and stockholders? equity1~
1\
11~
1H123$4____________________________15)Created by Morningstar Document Research.06(http://documentresearch.morningstar.com/2 ko{D,sg?=PF0*8X>
@z6655441111
l &np
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??2Boston MA 02116
Balance SheetBalance Sheet (1)
Cash FlowsBalance Sheet (2)!3 Cash and Cash Equivalents and7 5 Fixed Assets6 Intangible Assets Net!7 Net Loss Per Share Available !Warrants to Purchase Common Sto10 Other Accrued Expenses11 Fair Value MeasurementsContingent Consideration12 StockBased Compensation12 StockBased C (1)
Stock options16 Restricted Stock Units13 Longterm DebtLeases!Research and Development Expens!Comparison of the three months !Comparison of the nine months e!Liquidity and Capital Resources34 EXHIBIT INDEX34 EXHIBIT INDE (1)35 36 SIGNATURES!Remainder of this page is inten!138 Entire Agreement The obligaPrior Inventions!2Due to a prior confidentiality Remainder of this page is (1)138 Entire Agreement The (1)Prior Invention (1)2Due to a prior (1) Remainder of this page is (2)138 Entire Agreement The (2)Prior Invention (2)2Due to a prior (2) Remainder of this page is (3)138 Entire Agreement The (3)Prior Invention (3)2Due to a prior (3) Remainder of this page is (4)138 Entire Agreement The (4)Prior Invention (4)2Due to a prior (4)!SECTION 302 OF THE SARBANESOXLESECTION 302 OF THE (1)!SECTION 906 OF THE SARBANESOXLESECTION 906 OF THE (1)U }I;}$ }}$ }}
$ }}$ }}$
&
%Paratek Pharmaceuticals, Inc.10Q
11/08/2017Income StatementThree Months Ended
Nine Months Ended
September 30,
September 30,
~
~
~
~
#License and royalty revenue~
2
$? ~
u
$?Operating expenses:
Research and development
~
B
~
~
^
~
6
"General and administrative~
n~
\
~
N
~
6&Impairment of intangible asset ? ?
~
?91Changes in fair value of contingent consideration~
~
Z
~
~
: Total operating expenses~
V=~
&i
~
fY
~
NLoss from operations~
~
ޖ
~
~
~
"Other income and expenses:
Interest expense~
~
2
~
~
Interest income~
~
~
N
~
ROther loss, net~
~
~
~
Loss before income taxes~
Ҳ~
Ҏ ~
&
~
"Provision for income taxes ? ?
~
?Net loss~
Ҳ~
Ҏ ~
b
~
#Other comprehensive income:
4,Unrealized (loss) gain on availableforsale~
B~
~
~
:securities, net of taxComprehensive loss~
~
~
b
~
B.&Net loss per share  basic and dilutedp=
ףp=
ף
RQ
(\2*Weighted average common shares outstanding
DJl}qe)J^p\q !"#$% Basic and diluted ~
jS ~
e
~
N
~
N !"$#____________________________1$)Created by Morningstar Document Research.0%(http://documentresearch.morningstar.com/d=PF0*8X>
@%%$$##
l 5Q
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??2Boston MA 02116
Balance SheetBalance Sheet (1)Income StatementBalance Sheet (2)!3 Cash and Cash Equivalents and7 5 Fixed Assets6 Intangible Assets Net!7 Net Loss Per Share Available !Warrants to Purchase Common Sto10 Other Accrued Expenses11 Fair Value MeasurementsContingent Consideration12 StockBased Compensation12 StockBased C (1)
Stock options16 Restricted Stock Units13 Longterm DebtLeases!Research and Development Expens!Comparison of the three months !Comparison of the nine months e!Liquidity and Capital Resources34 EXHIBIT INDEX34 EXHIBIT INDE (1)35 36 SIGNATURES!Remainder of this page is inten!138 Entire Agreement The obligaPrior Inventions!2Due to a prior confidentiality Remainder of this page is (1)138 Entire Agreement The (1)Prior Invention (1)2Due to a prior (1) Remainder of this page is (2)138 Entire Agreement The (2)Prior Invention (2)2Due to a prior (2) Remainder of this page is (3)138 Entire Agreement The (3)Prior Invention (3)2Due to a prior (3) Remainder of this page is (4)138 Entire Agreement The (4)Prior Invention (4)2Due to a prior (4)!SECTION 302 OF THE SARBANESOXLESECTION 302 OF THE (1)!SECTION 906 OF THE SARBANESOXLESECTION 906 OF THE (1)U }:}$ }I}$ }U}$
5
%Paratek Pharmaceuticals, Inc.10Q
11/08/2017
Cash Flows!For the Nine Months Ended
September 30,
~
~
Net loss~
b~
0(Adjustments to reconcile net loss to net*
"cash used in operating activities:%Depreciation and amortization~
N~
( Stockbased compensation expense~
j~
~ Noncash interest expense~
~
Noncash interest income ?~
V&Impairment of intangible asset~
?80Change in fair value of contingent consideration~
~
:3+Changes in operating assets and liabilities%Accounts receivable and other current~
V~
6Hassets1)Purchase of prepaid interest  marketable~
?
securities%Accounts payable and accrued expenses~
j~
*"Other liabilities and other assets~
z~
*%Net cash used in operating activities~
~
VInvesting activities%Purchase of fixed assets, net~
~
)!Purchase of marketable securities~
R~
N.&Proceeds from maturities of marketable~
ڸ~
D=lwk"9wZLI3wj ! " # $ % & ' ( ) * + ,  . / 0 1 2 3 4
securities.!&Increase (decrease) in restricted cash!!~
!>
!!!~
!N!"%Net cash used in investing activities""~
"2"""~
"v"#Financing activities########1$)Proceeds from issuance of longterm debt,$$~
$$$$ $?$%net of costs/&'Proceeds from exercise of stock options&&~
&&&&~
&.&*'"Proceeds from sale of common stock''~
''''~
''1()Net cash provided by financing activities((~
(ʢ(((~
(ʽ(1))Net decrease in cash and cash equivalents))~
))))~
)7).*&Cash and cash equivalents at beginning**~
*;***~
**+ of period2,*Cash and cash equivalents at end of period,~
,,,~
,*;,%SUPPLEMENTAL DISCLOSURES OF CASH FLOW.INFORMATION/Cash paid for interest/~
/$//
/$?/01$2____________________________13)Created by Morningstar Document Research.04(http://documentresearch.morningstar.com/.\ T?f4v_=PF0*8X>
@j
443322////,,,,
l `
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??2Boston MA 02116
Balance SheetBalance Sheet (1)Income Statement
Cash Flows!3 Cash and Cash Equivalents and7 5 Fixed Assets6 Intangible Assets Net!7 Net Loss Per Share Available !Warrants to Purchase Common Sto10 Other Accrued Expenses11 Fair Value MeasurementsContingent Consideration12 StockBased Compensation12 StockBased C (1)
Stock options16 Restricted Stock Units13 Longterm DebtLeases!Research and Development Expens!Comparison of the three months !Comparison of the nine months e!Liquidity and Capital Resources34 EXHIBIT INDEX34 EXHIBIT INDE (1)35 36 SIGNATURES!Remainder of this page is inten!138 Entire Agreement The obligaPrior Inventions!2Due to a prior confidentiality Remainder of this page is (1)138 Entire Agreement The (1)Prior Invention (1)2Due to a prior (1) Remainder of this page is (2)138 Entire Agreement The (2)Prior Invention (2)2Due to a prior (2) Remainder of this page is (3)138 Entire Agreement The (3)Prior Invention (3)2Due to a prior (3) Remainder of this page is (4)138 Entire Agreement The (4)Prior Invention (4)2Due to a prior (4)!SECTION 302 OF THE SARBANESOXLESECTION 302 OF THE (1)!SECTION 906 OF THE SARBANESOXLESECTION 906 OF THE (1)U }=}$}$ }U}$
%Paratek Pharmaceuticals, Inc.10Q
11/08/2017
Balance Sheet&Balance sheet reclassification
Amount ($). &Increase to additional paidin capital" Additional paidincapital ~

%resulting from the Company's election.&to recognize forfeitures as they occur4,rather than applying an estimated forfeiture
rate;3Charge to accumulated deficit for cumulativeeffectAccumulated deficit~
/'adjustment from adoption of ASU 201609$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,!thzI?=PF0*8X>
@"
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??2Boston MA 02116
Balance SheetBalance Sheet (1)Income Statement
Cash FlowsBalance Sheet (2)7 5 Fixed Assets6 Intangible Assets Net!7 Net Loss Per Share Available !Warrants to Purchase Common Sto10 Other Accrued Expenses11 Fair Value MeasurementsContingent Consideration12 StockBased Compensation12 StockBased C (1)
Stock options16 Restricted Stock Units13 Longterm DebtLeases!Research and Development Expens!Comparison of the three months !Comparison of the nine months e!Liquidity and Capital Resources34 EXHIBIT INDEX34 EXHIBIT INDE (1)35 36 SIGNATURES!Remainder of this page is inten!138 Entire Agreement The obligaPrior Inventions!2Due to a prior confidentiality Remainder of this page is (1)138 Entire Agreement The (1)Prior Invention (1)2Due to a prior (1) Remainder of this page is (2)138 Entire Agreement The (2)Prior Invention (2)2Due to a prior (2) Remainder of this page is (3)138 Entire Agreement The (3)Prior Invention (3)2Due to a prior (3) Remainder of this page is (4)138 Entire Agreement The (4)Prior Invention (4)2Due to a prior (4)!SECTION 302 OF THE SARBANESOXLESECTION 302 OF THE (1)!SECTION 906 OF THE SARBANESOXLESECTION 906 OF THE (1)U }}$ }
}$ }$}
$ }$}$ }
}$
%Paratek Pharmaceuticals, Inc.10Q
11/08/2017>63. Cash and Cash Equivalents and Marketable SecuritiesAmortized CostUnrealized Gains
Unrealized Losses
Fair Value September 30, 2017
U.S. treasury securities
~
b
$?
~
~
&
Government agencies~
?
~
~
Total~
v
$? ~
~
6
December 31, 2016
U.S. treasury securities~
$? ~
~
rGovernment agencies~
~
?
~
Total~
R~
~
~
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/0H
cWK?jAd
=PF0*8X>
@
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??2Boston MA 02116
Balance SheetBalance Sheet (1)Income Statement
Cash FlowsBalance Sheet (2)!3 Cash and Cash Equivalents and6 Intangible Assets Net!7 Net Loss Per Share Available !Warrants to Purchase Common Sto10 Other Accrued Expenses11 Fair Value MeasurementsContingent Consideration12 StockBased Compensation12 StockBased C (1)
Stock options16 Restricted Stock Units13 Longterm DebtLeases!Research and Development Expens!Comparison of the three months !Comparison of the nine months e!Liquidity and Capital Resources34 EXHIBIT INDEX34 EXHIBIT INDE (1)35 36 SIGNATURES!Remainder of this page is inten!138 Entire Agreement The obligaPrior Inventions!2Due to a prior confidentiality Remainder of this page is (1)138 Entire Agreement The (1)Prior Invention (1)2Due to a prior (1) Remainder of this page is (2)138 Entire Agreement The (2)Prior Invention (2)2Due to a prior (2) Remainder of this page is (3)138 Entire Agreement The (3)Prior Invention (3)2Due to a prior (3) Remainder of this page is (4)138 Entire Agreement The (4)Prior Invention (4)2Due to a prior (4)!SECTION 302 OF THE SARBANESOXLESECTION 302 OF THE (1)!SECTION 906 OF THE SARBANESOXLESECTION 906 OF THE (1)U }8}$ }U}$ }U}$
%Paratek Pharmaceuticals, Inc.10Q
11/08/20177 5. Fixed Assets
September 30,December 31, ~
~
Office equipment
~
~
Computer equipment~
~
Computer software~
N~
N
Leasehold improvements
~
~
&
Constructioninprogress ?~
Gross fixed assets~
1~
f7/Less: Accumulated depreciation and amortization~
~
.Net fixed assets~
~
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/2pdC@3j=PF0*8X>
@Z
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??2Boston MA 02116
Balance SheetBalance Sheet (1)Income Statement
Cash FlowsBalance Sheet (2)!3 Cash and Cash Equivalents and7 5 Fixed Assets!7 Net Loss Per Share Available !Warrants to Purchase Common Sto10 Other Accrued Expenses11 Fair Value MeasurementsContingent Consideration12 StockBased Compensation12 StockBased C (1)
Stock options16 Restricted Stock Units13 Longterm DebtLeases!Research and Development Expens!Comparison of the three months !Comparison of the nine months e!Liquidity and Capital Resources34 EXHIBIT INDEX34 EXHIBIT INDE (1)35 36 SIGNATURES!Remainder of this page is inten!138 Entire Agreement The obligaPrior Inventions!2Due to a prior confidentiality Remainder of this page is (1)138 Entire Agreement The (1)Prior Invention (1)2Due to a prior (1) Remainder of this page is (2)138 Entire Agreement The (2)Prior Invention (2)2Due to a prior (2) Remainder of this page is (3)138 Entire Agreement The (3)Prior Invention (3)2Due to a prior (3) Remainder of this page is (4)138 Entire Agreement The (4)Prior Invention (4)2Due to a prior (4)!SECTION 302 OF THE SARBANESOXLESECTION 302 OF THE (1)!SECTION 906 OF THE SARBANESOXLESECTION 906 OF THE (1)U }$}$ }U}$ }U}$
%Paratek Pharmaceuticals, Inc.10Q
11/08/2017!6. Intangible Assets, Net
September 30,December 31, ~
~
!
Intermezzo product rights
~
R
~
TO2070 asset~
~
Gross intangible assets~
~
&
Less: Accumulated amortization
~
~
.
Net intangible assets~
~
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,th\2.3'=PF0*8X>
@Z
l M
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??2Boston MA 02116
Balance SheetBalance Sheet (1)Income Statement
Cash FlowsBalance Sheet (2)!3 Cash and Cash Equivalents and7 5 Fixed Assets6 Intangible Assets Net!Warrants to Purchase Common Sto10 Other Accrued Expenses11 Fair Value MeasurementsContingent Consideration12 StockBased Compensation12 StockBased C (1)
Stock options16 Restricted Stock Units13 Longterm DebtLeases!Research and Development Expens!Comparison of the three months !Comparison of the nine months e!Liquidity and Capital Resources34 EXHIBIT INDEX34 EXHIBIT INDE (1)35 36 SIGNATURES!Remainder of this page is inten!138 Entire Agreement The obligaPrior Inventions!2Due to a prior confidentiality Remainder of this page is (1)138 Entire Agreement The (1)Prior Invention (1)2Due to a prior (1) Remainder of this page is (2)138 Entire Agreement The (2)Prior Invention (2)2Due to a prior (2) Remainder of this page is (3)138 Entire Agreement The (3)Prior Invention (3)2Due to a prior (3) Remainder of this page is (4)138 Entire Agreement The (4)Prior Invention (4)2Due to a prior (4)!SECTION 302 OF THE SARBANESOXLESECTION 302 OF THE (1)!SECTION 906 OF THE SARBANESOXLESECTION 906 OF THE (1)U }6}$ }y}$ }y}$
%Paratek Pharmaceuticals, Inc.10Q
11/08/2017>67. Net Loss Per Share Available to Common Stockholders
September 30, ~
~
0
(Excluded potentially dilutive securities
(1) :%Shares subject to outstanding options~
F=~
to purchase common stock'Unvested restricted stock units~
kH~
.&Shares subject to warrants to purchase~
r~
common stock5Shares issuable under employee stock purchase~
:~
:planTotals~
*~
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/8cWK?pY>dT=PF0*8X>
@2
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??2Boston MA 02116
Balance SheetBalance Sheet (1)Income Statement
Cash FlowsBalance Sheet (2)!3 Cash and Cash Equivalents and7 5 Fixed Assets6 Intangible Assets Net!7 Net Loss Per Share Available 10 Other Accrued Expenses11 Fair Value MeasurementsContingent Consideration12 StockBased Compensation12 StockBased C (1)
Stock options16 Restricted Stock Units13 Longterm DebtLeases!Research and Development Expens!Comparison of the three months !Comparison of the nine months e!Liquidity and Capital Resources34 EXHIBIT INDEX34 EXHIBIT INDE (1)35 36 SIGNATURES!Remainder of this page is inten!138 Entire Agreement The obligaPrior Inventions!2Due to a prior confidentiality Remainder of this page is (1)138 Entire Agreement The (1)Prior Invention (1)2Due to a prior (1) Remainder of this page is (2)138 Entire Agreement The (2)Prior Invention (2)2Due to a prior (2) Remainder of this page is (3)138 Entire Agreement The (3)Prior Invention (3)2Due to a prior (3) Remainder of this page is (4)138 Entire Agreement The (4)Prior Invention (4)2Due to a prior (4)!SECTION 302 OF THE SARBANESOXLESECTION 302 OF THE (1)!SECTION 906 OF THE SARBANESOXLESECTION 906 OF THE (1)U }0}$ } }$
%Paratek Pharmaceuticals, Inc.10Q
11/08/2017)!Warrants to Purchase Common StockJune 30, ~
Volatility
33333P@
%0(Weighted average riskfree interest rate? %Expected dividend yield~
%+
#Expected life of options (in years)
~
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/*hxl`T>{oG=PF0*8X>
@*
l x
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??2Boston MA 02116
Balance SheetBalance Sheet (1)Income Statement
Cash FlowsBalance Sheet (2)!3 Cash and Cash Equivalents and7 5 Fixed Assets6 Intangible Assets Net!7 Net Loss Per Share Available !Warrants to Purchase Common Sto11 Fair Value MeasurementsContingent Consideration12 StockBased Compensation12 StockBased C (1)
Stock options16 Restricted Stock Units13 Longterm DebtLeases!Research and Development Expens!Comparison of the three months !Comparison of the nine months e!Liquidity and Capital Resources34 EXHIBIT INDEX34 EXHIBIT INDE (1)35 36 SIGNATURES!Remainder of this page is inten!138 Entire Agreement The obligaPrior Inventions!2Due to a prior confidentiality Remainder of this page is (1)138 Entire Agreement The (1)Prior Invention (1)2Due to a prior (1) Remainder of this page is (2)138 Entire Agreement The (2)Prior Invention (2)2Due to a prior (2) Remainder of this page is (3)138 Entire Agreement The (3)Prior Invention (3)2Due to a prior (3) Remainder of this page is (4)138 Entire Agreement The (4)Prior Invention (4)2Due to a prior (4)!SECTION 302 OF THE SARBANESOXLESECTION 302 OF THE (1)!SECTION 906 OF THE SARBANESOXLESECTION 906 OF THE (1)U }$}$ }U}$ }U}$
%Paratek Pharmaceuticals, Inc.10Q
11/08/2017"10. Other Accrued Expenses
September 30,December 31, ~
~
Accrued legal costs
~
j
~
Accrued compensation~
(~
(Intermezzo payable~
v~
!
Accrued professional fees
~
~
z
&Accrued contract manufacturing~
:~
R
Accrued other~
:~
Total~
R~
rd$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/09sg[(=PF0*8X>
@J
l "*
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??2Boston MA 02116
Balance SheetBalance Sheet (1)Income Statement
Cash FlowsBalance Sheet (2)!3 Cash and Cash Equivalents and7 5 Fixed Assets6 Intangible Assets Net!7 Net Loss Per Share Available !Warrants to Purchase Common Sto10 Other Accrued ExpensesContingent Consideration12 StockBased Compensation12 StockBased C (1)
Stock options16 Restricted Stock Units13 Longterm DebtLeases!Research and Development Expens!Comparison of the three months !Comparison of the nine months e!Liquidity and Capital Resources34 EXHIBIT INDEX34 EXHIBIT INDE (1)35 36 SIGNATURES!Remainder of this page is inten!138 Entire Agreement The obligaPrior Inventions!2Due to a prior confidentiality Remainder of this page is (1)138 Entire Agreement The (1)Prior Invention (1)2Due to a prior (1) Remainder of this page is (2)138 Entire Agreement The (2)Prior Invention (2)2Due to a prior (2) Remainder of this page is (3)138 Entire Agreement The (3)Prior Invention (3)2Due to a prior (3) Remainder of this page is (4)138 Entire Agreement The (4)Prior Invention (4)2Due to a prior (4)!SECTION 302 OF THE SARBANESOXLESECTION 302 OF THE (1)!SECTION 906 OF THE SARBANESOXLESECTION 906 OF THE (1)U }}$ }$}$ }}
$ }$}$ }
}$
"
%Paratek Pharmaceuticals, Inc.10Q
11/08/2017#11. Fair Value MeasurementsDescriptionQuotedSignificant
Significant
Total Prices in
Other
Unobservable
Active
Observable
InputsMarketsInputs
(Level 3) (Level 1) (Level 2)
September 30, 2017
Assets:
U.S. treasury securities~
&
$?
$?
~
&Government agencies ?~
?
~
Total Assets~
&~
$?
~
6Liabilities:
Contingent obligations
$?
$? ~
R
~
RTotal Liabilities
$?
$? ~
R
~
RDecember 31, 2016
Assets:
U.S. treasury securities~
r
$?
$?
~
rGovernment agencies ?~
?
~
Total Assets~
r~
$?
~
Liabilities:
Contingent obligations
$?
$? ~
>
~
>
Total Liabilities
$?
$? ~
>
~
>
$____________________________Dl~rfZAh&q p) !1 )Created by Morningstar Document Research.0!(http://documentresearch.morningstar.com/=PF0*8X>
@3!!
l "
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??2Boston MA 02116
Balance SheetBalance Sheet (1)Income Statement
Cash FlowsBalance Sheet (2)!3 Cash and Cash Equivalents and7 5 Fixed Assets6 Intangible Assets Net!7 Net Loss Per Share Available !Warrants to Purchase Common Sto10 Other Accrued Expenses11 Fair Value Measurements12 StockBased Compensation12 StockBased C (1)
Stock options16 Restricted Stock Units13 Longterm DebtLeases!Research and Development Expens!Comparison of the three months !Comparison of the nine months e!Liquidity and Capital Resources34 EXHIBIT INDEX34 EXHIBIT INDE (1)35 36 SIGNATURES!Remainder of this page is inten!138 Entire Agreement The obligaPrior Inventions!2Due to a prior confidentiality Remainder of this page is (1)138 Entire Agreement The (1)Prior Invention (1)2Due to a prior (1) Remainder of this page is (2)138 Entire Agreement The (2)Prior Invention (2)2Due to a prior (2) Remainder of this page is (3)138 Entire Agreement The (3)Prior Invention (3)2Due to a prior (3) Remainder of this page is (4)138 Entire Agreement The (4)Prior Invention (4)2Due to a prior (4)!SECTION 302 OF THE SARBANESOXLESECTION 302 OF THE (1)!SECTION 906 OF THE SARBANESOXLESECTION 906 OF THE (1)U }$}$ } }$
%Paratek Pharmaceuticals, Inc.10Q
11/08/2017 Contingent Consideration
Contingent
liability?
former Transceptstockholders%
Balances At December 31, 2016
~
>
Change in fair value~
&Balances At September 30, 2017~
R$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/.ui]#n}qe==PF0*8X>
@R
l D1
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??2Boston MA 02116
Balance SheetBalance Sheet (1)Income Statement
Cash FlowsBalance Sheet (2)!3 Cash and Cash Equivalents and7 5 Fixed Assets6 Intangible Assets Net!7 Net Loss Per Share Available !Warrants to Purchase Common Sto10 Other Accrued Expenses11 Fair Value MeasurementsContingent Consideration12 StockBased C (1)
Stock options16 Restricted Stock Units13 Longterm DebtLeases!Research and Development Expens!Comparison of the three months !Comparison of the nine months e!Liquidity and Capital Resources34 EXHIBIT INDEX34 EXHIBIT INDE (1)35 36 SIGNATURES!Remainder of this page is inten!138 Entire Agreement The obligaPrior Inventions!2Due to a prior confidentiality Remainder of this page is (1)138 Entire Agreement The (1)Prior Invention (1)2Due to a prior (1) Remainder of this page is (2)138 Entire Agreement The (2)Prior Invention (2)2Due to a prior (2) Remainder of this page is (3)138 Entire Agreement The (3)Prior Invention (3)2Due to a prior (3) Remainder of this page is (4)138 Entire Agreement The (4)Prior Invention (4)2Due to a prior (4)!SECTION 302 OF THE SARBANESOXLESECTION 302 OF THE (1)!SECTION 906 OF THE SARBANESOXLESECTION 906 OF THE (1)U }0.}$ }
}$ }
}
$ }
}$ }
}$
%Paratek Pharmaceuticals, Inc.10Q
11/08/2017$12. StockBased Compensation( Three Months Ended September 30, '
Nine Months Ended September 30, ~
~
~
~
(
Research and development expense
~
~
~
bC
~
'
*"General and administrative expense~
",~
~
~
W.&Total stockbased compensation expense~
?~
) ~
j
~
~
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/(sT}qeY"^h^=PF0*8X>
@
l #?
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??2Boston MA 02116
Balance SheetBalance Sheet (1)Income Statement
Cash FlowsBalance Sheet (2)!3 Cash and Cash Equivalents and7 5 Fixed Assets6 Intangible Assets Net!7 Net Loss Per Share Available !Warrants to Purchase Common Sto10 Other Accrued Expenses11 Fair Value MeasurementsContingent Consideration12 StockBased Compensation
Stock options16 Restricted Stock Units13 Longterm DebtLeases!Research and Development Expens!Comparison of the three months !Comparison of the nine months e!Liquidity and Capital Resources34 EXHIBIT INDEX34 EXHIBIT INDE (1)35 36 SIGNATURES!Remainder of this page is inten!138 Entire Agreement The obligaPrior Inventions!2Due to a prior confidentiality Remainder of this page is (1)138 Entire Agreement The (1)Prior Invention (1)2Due to a prior (1) Remainder of this page is (2)138 Entire Agreement The (2)Prior Invention (2)2Due to a prior (2) Remainder of this page is (3)138 Entire Agreement The (3)Prior Invention (3)2Due to a prior (3) Remainder of this page is (4)138 Entire Agreement The (4)Prior Invention (4)2Due to a prior (4)!SECTION 302 OF THE SARBANESOXLESECTION 302 OF THE (1)!SECTION 906 OF THE SARBANESOXLESECTION 906 OF THE (1)U }0}$ } }$}$ } }$
%Paratek Pharmaceuticals, Inc.10Q
11/08/2017$12. StockBased Compensation'Nine Months Ended September 30, ~
~
Volatility
33333R@
%
`R@
%0(Weighted average riskfree interest rate~
%ffffff? %Expected dividend yield~
%~
%+
#Expected life of options (in years)
333333@
333333@
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/*h}qeY
.l`T,=PF0*8X>
@2
l T
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??2Boston MA 02116
Balance SheetBalance Sheet (1)Income Statement
Cash FlowsBalance Sheet (2)!3 Cash and Cash Equivalents and7 5 Fixed Assets6 Intangible Assets Net!7 Net Loss Per Share Available !Warrants to Purchase Common Sto10 Other Accrued Expenses11 Fair Value MeasurementsContingent Consideration12 StockBased Compensation12 StockBased C (1)16 Restricted Stock Units13 Longterm DebtLeases!Research and Development Expens!Comparison of the three months !Comparison of the nine months e!Liquidity and Capital Resources34 EXHIBIT INDEX34 EXHIBIT INDE (1)35 36 SIGNATURES!Remainder of this page is inten!138 Entire Agreement The obligaPrior Inventions!2Due to a prior confidentiality Remainder of this page is (1)138 Entire Agreement The (1)Prior Invention (1)2Due to a prior (1) Remainder of this page is (2)138 Entire Agreement The (2)Prior Invention (2)2Due to a prior (2) Remainder of this page is (3)138 Entire Agreement The (3)Prior Invention (3)2Due to a prior (3) Remainder of this page is (4)138 Entire Agreement The (4)Prior Invention (4)2Due to a prior (4)!SECTION 302 OF THE SARBANESOXLESECTION 302 OF THE (1)!SECTION 906 OF THE SARBANESOXLESECTION 906 OF THE (1)U }U5}$ }y}$ }
}
$ } }$
%Paratek Pharmaceuticals, Inc.10Q
11/08/2017
Stock optionsNumberWeighted
Weighted
Aggregate of Shares Average
Average
Intrinsic
Exercise
Remaining
Value
Price
Contractual
(in thousands)
Term
(in years)( Outstanding at December 31, 2016~
zG0@
ףp= @
~
Granted~
7Gz1@
Exercised~
RQ@
Expired or Forfeited~
&
ףp=
1@
)!Outstanding at September 30, 2017~
F=(\0@
Q @
~
)!Exercisable at September 30, 2017~
uw\(0@
@
~
4,Vested and expected to vest at September 30,~
F=(\0@
Q @
~
~
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/8v
thK {=/#=PF0*8X>
@
l c
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??2Boston MA 02116
Balance SheetBalance Sheet (1)Income Statement
Cash FlowsBalance Sheet (2)!3 Cash and Cash Equivalents and7 5 Fixed Assets6 Intangible Assets Net!7 Net Loss Per Share Available !Warrants to Purchase Common Sto10 Other Accrued Expenses11 Fair Value MeasurementsContingent Consideration12 StockBased Compensation12 StockBased C (1)
Stock options13 Longterm DebtLeases!Research and Development Expens!Comparison of the three months !Comparison of the nine months e!Liquidity and Capital Resources34 EXHIBIT INDEX34 EXHIBIT INDE (1)35 36 SIGNATURES!Remainder of this page is inten!138 Entire Agreement The obligaPrior Inventions!2Due to a prior confidentiality Remainder of this page is (1)138 Entire Agreement The (1)Prior Invention (1)2Due to a prior (1) Remainder of this page is (2)138 Entire Agreement The (2)Prior Invention (2)2Due to a prior (2) Remainder of this page is (3)138 Entire Agreement The (3)Prior Invention (3)2Due to a prior (3) Remainder of this page is (4)138 Entire Agreement The (4)Prior Invention (4)2Due to a prior (4)!SECTION 302 OF THE SARBANESOXLESECTION 302 OF THE (1)!SECTION 906 OF THE SARBANESOXLESECTION 906 OF THE (1)U }0.}$ }
}$ }
}$
%Paratek Pharmaceuticals, Inc.10Q
11/08/2017!16 Restricted Stock UnitsNumberWeighted of Shares Average
Grant Date
Fair Value%Unvested Balance At December 31, 2016~
µQ3@
Granted
~
B7
(\0@
Released~
NQk@ Cancelled~
Ҋ(\u+@.&Unvested Balance At September 30, 2017~
kHGzT2@$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/0
th\DYbWK?=PF0*8X>
@Z
l ap
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??2Boston MA 02116
Balance SheetBalance Sheet (1)Income Statement
Cash FlowsBalance Sheet (2)!3 Cash and Cash Equivalents and7 5 Fixed Assets6 Intangible Assets Net!7 Net Loss Per Share Available !Warrants to Purchase Common Sto10 Other Accrued Expenses11 Fair Value MeasurementsContingent Consideration12 StockBased Compensation12 StockBased C (1)
Stock options16 Restricted Stock UnitsLeases!Research and Development Expens!Comparison of the three months !Comparison of the nine months e!Liquidity and Capital Resources34 EXHIBIT INDEX34 EXHIBIT INDE (1)35 36 SIGNATURES!Remainder of this page is inten!138 Entire Agreement The obligaPrior Inventions!2Due to a prior confidentiality Remainder of this page is (1)138 Entire Agreement The (1)Prior Invention (1)2Due to a prior (1) Remainder of this page is (2)138 Entire Agreement The (2)Prior Invention (2)2Due to a prior (2) Remainder of this page is (3)138 Entire Agreement The (3)Prior Invention (3)2Due to a prior (3) Remainder of this page is (4)138 Entire Agreement The (4)Prior Invention (4)2Due to a prior (4)!SECTION 302 OF THE SARBANESOXLESECTION 302 OF THE (1)!SECTION 906 OF THE SARBANESOXLESECTION 906 OF THE (1)U }}$ }}$
%Paratek Pharmaceuticals, Inc.10Q
11/08/201713. Longterm DebtFiscal Year~
$? ~
?
~
~
~
~
]
2021 and Thereafter
?
Total~
B
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,{oci)b=PF0*8X>
@*
l 
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??2Boston MA 02116
Balance SheetBalance Sheet (1)Income Statement
Cash FlowsBalance Sheet (2)!3 Cash and Cash Equivalents and7 5 Fixed Assets6 Intangible Assets Net!7 Net Loss Per Share Available !Warrants to Purchase Common Sto10 Other Accrued Expenses11 Fair Value MeasurementsContingent Consideration12 StockBased Compensation12 StockBased C (1)
Stock options16 Restricted Stock Units13 Longterm Debt!Research and Development Expens!Comparison of the three months !Comparison of the nine months e!Liquidity and Capital Resources34 EXHIBIT INDEX34 EXHIBIT INDE (1)35 36 SIGNATURES!Remainder of this page is inten!138 Entire Agreement The obligaPrior Inventions!2Due to a prior confidentiality Remainder of this page is (1)138 Entire Agreement The (1)Prior Invention (1)2Due to a prior (1) Remainder of this page is (2)138 Entire Agreement The (2)Prior Invention (2)2Due to a prior (2) Remainder of this page is (3)138 Entire Agreement The (3)Prior Invention (3)2Due to a prior (3) Remainder of this page is (4)138 Entire Agreement The (4)Prior Invention (4)2Due to a prior (4)!SECTION 302 OF THE SARBANESOXLESECTION 302 OF THE (1)!SECTION 906 OF THE SARBANESOXLESECTION 906 OF THE (1)U }}$ }
}$
%Paratek Pharmaceuticals, Inc.10Q
11/08/2017LeasesFiscal Year Remainder of 2017 ~
~
~
~
~
~
~
j~
~
2022 and Thereafter~
:
Total~
v]$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/.{o(e%]QE=PF0*8X>
@*
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??2Boston MA 02116
Balance SheetBalance Sheet (1)Income Statement
Cash FlowsBalance Sheet (2)!3 Cash and Cash Equivalents and7 5 Fixed Assets6 Intangible Assets Net!7 Net Loss Per Share Available !Warrants to Purchase Common Sto10 Other Accrued Expenses11 Fair Value MeasurementsContingent Consideration12 StockBased Compensation12 StockBased C (1)
Stock options16 Restricted Stock Units13 Longterm DebtLeases!Comparison of the three months !Comparison of the nine months e!Liquidity and Capital Resources34 EXHIBIT INDEX34 EXHIBIT INDE (1)35 36 SIGNATURES!Remainder of this page is inten!138 Entire Agreement The obligaPrior Inventions!2Due to a prior confidentiality Remainder of this page is (1)138 Entire Agreement The (1)Prior Invention (1)2Due to a prior (1) Remainder of this page is (2)138 Entire Agreement The (2)Prior Invention (2)2Due to a prior (2) Remainder of this page is (3)138 Entire Agreement The (3)Prior Invention (3)2Due to a prior (3) Remainder of this page is (4)138 Entire Agreement The (4)Prior Invention (4)2Due to a prior (4)!SECTION 302 OF THE SARBANESOXLESECTION 302 OF THE (1)!SECTION 906 OF THE SARBANESOXLESECTION 906 OF THE (1)U }+}$ }
}$ }
}
$ }}$ }
}$
%Paratek Pharmaceuticals, Inc.10Q
11/08/2017( Research and Development ExpenseThree Months Ended
Nine Months Ended
September 30,
September 30,
~
~
~
~
Omadacycline costs~
~
j ~
^
~
[,$Other research and development costs~
@~
r.
~
~
f
Total
~
B
~
~
^
~
6
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/*hymaU"*uiA=PF0*8X>
@
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??2Boston MA 02116
Balance SheetBalance Sheet (1)Income Statement
Cash FlowsBalance Sheet (2)!3 Cash and Cash Equivalents and7 5 Fixed Assets6 Intangible Assets Net!7 Net Loss Per Share Available !Warrants to Purchase Common Sto10 Other Accrued Expenses11 Fair Value MeasurementsContingent Consideration12 StockBased Compensation12 StockBased C (1)
Stock options16 Restricted Stock Units13 Longterm DebtLeases!Research and Development Expens!Comparison of the nine months e!Liquidity and Capital Resources34 EXHIBIT INDEX34 EXHIBIT INDE (1)35 36 SIGNATURES!Remainder of this page is inten!138 Entire Agreement The obligaPrior Inventions!2Due to a prior confidentiality Remainder of this page is (1)138 Entire Agreement The (1)Prior Invention (1)2Due to a prior (1) Remainder of this page is (2)138 Entire Agreement The (2)Prior Invention (2)2Due to a prior (2) Remainder of this page is (3)138 Entire Agreement The (3)Prior Invention (3)2Due to a prior (3) Remainder of this page is (4)138 Entire Agreement The (4)Prior Invention (4)2Due to a prior (4)!SECTION 302 OF THE SARBANESOXLESECTION 302 OF THE (1)!SECTION 906 OF THE SARBANESOXLESECTION 906 OF THE (1)U }I;}$ }}$ }}
$ }}$
%Paratek Pharmaceuticals, Inc.10Q
11/08/2017H@Comparison of the three months ended September 30, 2017 and 2016Three Months Ended
September 30,
(in thousands)
~
~
$ Change
#License and royalty revenue~
2
$? ~
2Operating expenses:
Research and development
~
B
~
~
j
"General and administrative~
n~
\
~
z#91Changes in fair value of contingent consideration~
~
Z
~
R Total operating expenses~
V=~
&i
~
2Loss from operations~
~
ޖ
~
,"Other income and expenses:
Interest expense~
~
2
~
Interest income~
~
~
BOther loss, net~
~
~
Net Loss~
Ҳ~
Ҏ ~
$$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/<*
YMA5gBoI5o=PF0*8X>
@r
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??2Boston MA 02116
Balance SheetBalance Sheet (1)Income Statement
Cash FlowsBalance Sheet (2)!3 Cash and Cash Equivalents and7 5 Fixed Assets6 Intangible Assets Net!7 Net Loss Per Share Available !Warrants to Purchase Common Sto10 Other Accrued Expenses11 Fair Value MeasurementsContingent Consideration12 StockBased Compensation12 StockBased C (1)
Stock options16 Restricted Stock Units13 Longterm DebtLeases!Research and Development Expens!Comparison of the three months !Liquidity and Capital Resources34 EXHIBIT INDEX34 EXHIBIT INDE (1)35 36 SIGNATURES!Remainder of this page is inten!138 Entire Agreement The obligaPrior Inventions!2Due to a prior confidentiality Remainder of this page is (1)138 Entire Agreement The (1)Prior Invention (1)2Due to a prior (1) Remainder of this page is (2)138 Entire Agreement The (2)Prior Invention (2)2Due to a prior (2) Remainder of this page is (3)138 Entire Agreement The (3)Prior Invention (3)2Due to a prior (3) Remainder of this page is (4)138 Entire Agreement The (4)Prior Invention (4)2Due to a prior (4)!SECTION 302 OF THE SARBANESOXLESECTION 302 OF THE (1)!SECTION 906 OF THE SARBANESOXLESECTION 906 OF THE (1)U }I;}$ }}$ }}
$ }
}$
%Paratek Pharmaceuticals, Inc.10Q
11/08/2017G?Comparison of the nine months ended September 30, 2017 and 2016Nine Months Ended
September 30,
(in thousands)
~
~
$ Change
#License and royalty revenue~
u
$? ~
uOperating expenses:
Research and development
~
^
~
6
~
*
"General and administrative~
N~
6
~
nT&Impairment of intangible asset~
?
~
91Changes in fair value of contingent consideration~
~
:
~
Total operating expenses~
fY~
N
~
?Loss from operations~
~~
~
6"Other income and expenses:
Interest expense~
~
~
Interest income~
N~
R
~
Other loss, net~
~
~
Loss before income taxes~
&~
~
%"Provision for income taxes~
?
~
Net Loss~
b~
~
Z$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/BtXZNB6iDB)x'a=PF0*8X>
@
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??2Boston MA 02116
Balance SheetBalance Sheet (1)Income Statement
Cash FlowsBalance Sheet (2)!3 Cash and Cash Equivalents and7 5 Fixed Assets6 Intangible Assets Net!7 Net Loss Per Share Available !Warrants to Purchase Common Sto10 Other Accrued Expenses11 Fair Value MeasurementsContingent Consideration12 StockBased Compensation12 StockBased C (1)
Stock options16 Restricted Stock Units13 Longterm DebtLeases!Research and Development Expens!Comparison of the three months !Comparison of the nine months e34 EXHIBIT INDEX34 EXHIBIT INDE (1)35 36 SIGNATURES!Remainder of this page is inten!138 Entire Agreement The obligaPrior Inventions!2Due to a prior confidentiality Remainder of this page is (1)138 Entire Agreement The (1)Prior Invention (1)2Due to a prior (1) Remainder of this page is (2)138 Entire Agreement The (2)Prior Invention (2)2Due to a prior (2) Remainder of this page is (3)138 Entire Agreement The (3)Prior Invention (3)2Due to a prior (3) Remainder of this page is (4)138 Entire Agreement The (4)Prior Invention (4)2Due to a prior (4)!SECTION 302 OF THE SARBANESOXLESECTION 302 OF THE (1)!SECTION 906 OF THE SARBANESOXLESECTION 906 OF THE (1)U }1}$
%Paratek Pharmaceuticals, Inc.10Q
11/08/2017'Liquidity and Capital ResourcesNine Months Ended
September 30,
(in thousands)
~
~
%Net cash used in operating activities~
~
V%Net cash used in investing activities~
2~
v1
)Net cash provided by financing activities
~
ʢ
~
ʽ
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/*"hznbV~=PF0*8X>
@j
l <
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??2Boston MA 02116
Balance SheetBalance Sheet (1)Income Statement
Cash FlowsBalance Sheet (2)!3 Cash and Cash Equivalents and7 5 Fixed Assets6 Intangible Assets Net!7 Net Loss Per Share Available !Warrants to Purchase Common Sto10 Other Accrued Expenses11 Fair Value MeasurementsContingent Consideration12 StockBased Compensation12 StockBased C (1)
Stock options16 Restricted Stock Units13 Longterm DebtLeases!Research and Development Expens!Comparison of the three months !Comparison of the nine months e!Liquidity and Capital Resources34 EXHIBIT INDE (1)35 36 SIGNATURES!Remainder of this page is inten!138 Entire Agreement The obligaPrior Inventions!2Due to a prior confidentiality Remainder of this page is (1)138 Entire Agreement The (1)Prior Invention (1)2Due to a prior (1) Remainder of this page is (2)138 Entire Agreement The (2)Prior Invention (2)2Due to a prior (2) Remainder of this page is (3)138 Entire Agreement The (3)Prior Invention (3)2Due to a prior (3) Remainder of this page is (4)138 Entire Agreement The (4)Prior Invention (4)2Due to a prior (4)!SECTION 302 OF THE SARBANESOXLESECTION 302 OF THE (1)!SECTION 906 OF THE SARBANESOXLESECTION 906 OF THE (1)U }I}$ }mB}$ }}$ }}$ }I } $ }
0
<
%Paratek Pharmaceuticals, Inc.10Q
11/08/201734 EXHIBIT INDEX!Incorporated by Reference
Exhibit Exhibit Description Schedule/ File Number Exhibit
Filing Date
No.
Form
@:2Amended and Restated Certificate of Incorporation.Form 8K 00136066@
October 31, 2014
@/'Certificate of Amendment of Amended andForm 8K 00136066 @
October 31, 2014.&Restated Certificate of Incorporation.
ffffff
@$Amended and Restated Bylaws.Form 8K 00136066@
April 16, 2015
ffffff@*"Specimen Common Stock Certificate.Form S3
333201458@
January 12, 2015
@?7Form of Warrant Agreement issued to Hercules TechnologyForm 8K 00136066ffffff@
October 5, 20152*II, L.P. and Hercules Technology III, L.P.
333333@4,Form of Warrant Agreement issued to HerculesForm 8K 00136066ffffff@
December 13, 20163+Technology II, L.P. and Hercules Technology III, L.P.
@1)Warrant, dated as of April 7, 2014 issued Form 10K 00136066q=
ףp$@
April 2, 2015.&to HBM Healthcare Investments (Cayman)Ltd.
D,l}qe4m.`=""J !"#$%&'()*+,./0123456789:; @ 2 *Warrant, dated as of April 18, 2014 issued Form 10K 00136066 (\u$@
April 2, 2015!!!!to K/S Danish BioVenture."""""""""" "
#ffffff@#1#)Warrant, dated as of April 7, 2014 issued## Form 10K## 00136066##{Gz$@# #
April 2, 2015$$$to Omega Fund III, L.P.%%%%%%%%%% %
& 10.1*+&0&(Employment Agreement, as amended, by and&&&&&&& &
''1')between the Company and Michael F. Bigham((#(dated as of August 4, 2017.)))))))))) )
* 10.2*+*0*(Employment Agreement, as amended, by and******* *
++1+)between the Company and William M. Haskel,,#,dated as of August 4, 2017. 
. 10.3*+.0.(Employment Agreement, as amended, by and....... .
//4/,between the Company and Evan Loh, M.D. dated000as of August 4, 2017.1111111111 1
2 10.4*+202(Employment Agreement, as amended, by and2222222 2
3303(between the Company and Douglas W. Pag?n44#4dated as of August 4, 2017.5555555555 5
6 10.5*+606(Employment Agreement, as amended, by and6666666 6
7727*between the Company and Adam Woodrow dated888as of August 4, 2017.$9____________________________1:)Created by Morningstar Document Research.0;(http://documentresearch.morningstar.com/<>'fS
UE@C
[=PF0*8X>
@";;
::
99
l 5
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??2Boston MA 02116
Balance SheetBalance Sheet (1)Income Statement
Cash FlowsBalance Sheet (2)!3 Cash and Cash Equivalents and7 5 Fixed Assets6 Intangible Assets Net!7 Net Loss Per Share Available !Warrants to Purchase Common Sto10 Other Accrued Expenses11 Fair Value MeasurementsContingent Consideration12 StockBased Compensation12 StockBased C (1)
Stock options16 Restricted Stock Units13 Longterm DebtLeases!Research and Development Expens!Comparison of the three months !Comparison of the nine months e!Liquidity and Capital Resources34 EXHIBIT INDEX35 36 SIGNATURES!Remainder of this page is inten!138 Entire Agreement The obligaPrior Inventions!2Due to a prior confidentiality Remainder of this page is (1)138 Entire Agreement The (1)Prior Invention (1)2Due to a prior (1) Remainder of this page is (2)138 Entire Agreement The (2)Prior Invention (2)2Due to a prior (2) Remainder of this page is (3)138 Entire Agreement The (3)Prior Invention (3)2Due to a prior (3) Remainder of this page is (4)138 Entire Agreement The (4)Prior Invention (4)2Due to a prior (4)!SECTION 302 OF THE SARBANESOXLESECTION 302 OF THE (1)!SECTION 906 OF THE SARBANESOXLESECTION 906 OF THE (1)U }}$ }IT}$ }}$ }}$ }I } $ }
5
%Paratek Pharmaceuticals, Inc.10Q
11/08/201734 EXHIBIT INDEX!Incorporated by Reference
Exhibit Exhibit Description Schedule/ File Number Exhibit
Filing Date
No.
Form
31.1*6.Certification of the Company?s Chief Executive
.
&Officer pursuant to Rule 13a14(a) and5Rule 15d14(a) of the Securities and Exchange4,Act of 1934, as amended, pursuant to Section.&302 of the SarbanesOxley Act of 2002.
31.2*6.Certification of the Company?s Chief Financial
.&Officer pursuant to Rule 13a14(a) and5Rule 15d14(a) of the Securities and Exchange4,Act of 1934, as amended, pursuant to Section.&302 of the SarbanesOxley Act of 2002.
32.1*6.Certification of the Company?s Chief Executive
3+Officer pursuant to 18 U.S.C. Section 1350,1)as adopted Pursuant to Section 906 of the#SarbanesOxley Act of 2002.
32.2*6.Certification of the Company?s Chief Financial
3+Officer pursuant to 18 U.S.C. Section 1350,1)as adopted Pursuant to Section 906 of theDh
l}qe4mi~@U~1n !"#$%&'()*+,./01234 # SarbanesOxley Act of 2002.!!!!!!!!!! !
"101.INS*""XBRL Instance Document.""""""" "
########## #
$101.SCH*$0$(XBRL Taxonomy Extension Schema Document.$$$$$$$ $
%%%%%%%%%% %
&101.CAL*&4&,XBRL Taxonomy Extension Calculation Linkbase&&&&&&& &
''' Document.(((((((((( (
)101.DEF*)3)+XBRL Taxonomy Extension Definition Linkbase))))))) )
*** Document.++++++++++ +
,101 . L A B*,N,FXBRL Ta xono m y E x t e ns i on La b e l s L i nkb a se,,,,,,, ,
Do c u m e n t ........... .
/101.PRE*/,/$XBRL Taxonomy Extension Presentation/////// /
000Linkbase Document.1$2____________________________13)Created by Morningstar Document Research.04(http://documentresearch.morningstar.com/.
=b&u
3u[=PF0*8X>
@"44
33
22
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??2Boston MA 02116
Balance SheetBalance Sheet (1)Income Statement
Cash FlowsBalance Sheet (2)!3 Cash and Cash Equivalents and7 5 Fixed Assets6 Intangible Assets Net!7 Net Loss Per Share Available !Warrants to Purchase Common Sto10 Other Accrued Expenses11 Fair Value MeasurementsContingent Consideration12 StockBased Compensation12 StockBased C (1)
Stock options16 Restricted Stock Units13 Longterm DebtLeases!Research and Development Expens!Comparison of the three months !Comparison of the nine months e!Liquidity and Capital Resources34 EXHIBIT INDEX34 EXHIBIT INDE (1)!Remainder of this page is inten!138 Entire Agreement The obligaPrior Inventions!2Due to a prior confidentiality Remainder of this page is (1)138 Entire Agreement The (1)Prior Invention (1)2Due to a prior (1) Remainder of this page is (2)138 Entire Agreement The (2)Prior Invention (2)2Due to a prior (2) Remainder of this page is (3)138 Entire Agreement The (3)Prior Invention (3)2Due to a prior (3) Remainder of this page is (4)138 Entire Agreement The (4)Prior Invention (4)2Due to a prior (4)!SECTION 302 OF THE SARBANESOXLESECTION 302 OF THE (1)!SECTION 906 OF THE SARBANESOXLESECTION 906 OF THE (1)U }}$ }U5
%Paratek Pharmaceuticals, Inc.10Q
11/08/201735 36 SIGNATURES%Paratek Pharmaceuticals, Inc.
By:
/s/ Michael F. BighamMichael F. Bigham,$Chairman and Chief Executive Officer
%
(Principal Executive Officer)By:/s/ Douglas W. Pag?nDouglas W. Pag?nChief Financial Officer4,(Principal Financial and Accounting Officer)$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/4q}qe<0w6h=PF0*8X>
@"
l s&
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??2Boston MA 02116
Balance SheetBalance Sheet (1)Income Statement
Cash FlowsBalance Sheet (2)!3 Cash and Cash Equivalents and7 5 Fixed Assets6 Intangible Assets Net!7 Net Loss Per Share Available !Warrants to Purchase Common Sto10 Other Accrued Expenses11 Fair Value MeasurementsContingent Consideration12 StockBased Compensation12 StockBased C (1)
Stock options16 Restricted Stock Units13 Longterm DebtLeases!Research and Development Expens!Comparison of the three months !Comparison of the nine months e!Liquidity and Capital Resources34 EXHIBIT INDEX34 EXHIBIT INDE (1)35 36 SIGNATURES!138 Entire Agreement The obligaPrior Inventions!2Due to a prior confidentiality Remainder of this page is (1)138 Entire Agreement The (1)Prior Invention (1)2Due to a prior (1) Remainder of this page is (2)138 Entire Agreement The (2)Prior Invention (2)2Due to a prior (2) Remainder of this page is (3)138 Entire Agreement The (3)Prior Invention (3)2Due to a prior (3) Remainder of this page is (4)138 Entire Agreement The (4)Prior Invention (4)2Due to a prior (4)!SECTION 302 OF THE SARBANESOXLESECTION 302 OF THE (1)!SECTION 906 OF THE SARBANESOXLESECTION 906 OF THE (1)U }1
%Paratek Pharmaceuticals, Inc.10Q
11/08/2017<4[Remainder of this page is intentionally left blank]
Sincerely,
%Paratek Pharmaceuticals, Inc.
/s/ Jeffrey Stein0(Jeffrey Stein, Director on behalf of the
Board Accepted:/s/ Michael F. BighamMichael F. BighamAugust 4, 2017Date$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/>0eYMA5p[O.=PF0*8X>
@
l 4
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??2Boston MA 02116
Balance SheetBalance Sheet (1)Income Statement
Cash FlowsBalance Sheet (2)!3 Cash and Cash Equivalents and7 5 Fixed Assets6 Intangible Assets Net!7 Net Loss Per Share Available !Warrants to Purchase Common Sto10 Other Accrued Expenses11 Fair Value MeasurementsContingent Consideration12 StockBased Compensation12 StockBased C (1)
Stock options16 Restricted Stock Units13 Longterm DebtLeases!Research and Development Expens!Comparison of the three months !Comparison of the nine months e!Liquidity and Capital Resources34 EXHIBIT INDEX34 EXHIBIT INDE (1)35 36 SIGNATURES!Remainder of this page is intenPrior Inventions!2Due to a prior confidentiality Remainder of this page is (1)138 Entire Agreement The (1)Prior Invention (1)2Due to a prior (1) Remainder of this page is (2)138 Entire Agreement The (2)Prior Invention (2)2Due to a prior (2) Remainder of this page is (3)138 Entire Agreement The (3)Prior Invention (3)2Due to a prior (3) Remainder of this page is (4)138 Entire Agreement The (4)Prior Invention (4)2Due to a prior (4)!SECTION 302 OF THE SARBANESOXLESECTION 302 OF THE (1)!SECTION 906 OF THE SARBANESOXLESECTION 906 OF THE (1)U }}$ }y
}:
%Paratek Pharmaceuticals, Inc.10Q
11/08/2017kc13.8 Entire Agreement. The obligations pursuant to Sections 1 and 2 (except Subsection 2.6) of this%Paratek Pharmaceuticals, Inc. Name Accepted and agreed:
0(I have read, understand, and Accept this5agreement and have been given the opportunity(Signature)5
to Review it with independent legal counsel .
By:(Signature)Title:
Date:
Date:Address:8075 Park Plaza, 4 th Floor, Boston, Massachusetts~
! :$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/86*1xEk=PF0*8X>
@Z
l @
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??2Boston MA 02116
Balance SheetBalance Sheet (1)Income Statement
Cash FlowsBalance Sheet (2)!3 Cash and Cash Equivalents and7 5 Fixed Assets6 Intangible Assets Net!7 Net Loss Per Share Available !Warrants to Purchase Common Sto10 Other Accrued Expenses11 Fair Value MeasurementsContingent Consideration12 StockBased Compensation12 StockBased C (1)
Stock options16 Restricted Stock Units13 Longterm DebtLeases!Research and Development Expens!Comparison of the three months !Comparison of the nine months e!Liquidity and Capital Resources34 EXHIBIT INDEX34 EXHIBIT INDE (1)35 36 SIGNATURES!Remainder of this page is inten!138 Entire Agreement The obliga!2Due to a prior confidentiality Remainder of this page is (1)138 Entire Agreement The (1)Prior Invention (1)2Due to a prior (1) Remainder of this page is (2)138 Entire Agreement The (2)Prior Invention (2)2Due to a prior (2) Remainder of this page is (3)138 Entire Agreement The (3)Prior Invention (3)2Due to a prior (3) Remainder of this page is (4)138 Entire Agreement The (4)Prior Invention (4)2Due to a prior (4)!SECTION 302 OF THE SARBANESOXLESECTION 302 OF THE (1)!SECTION 906 OF THE SARBANESOXLESECTION 906 OF THE (1)U }y
}$ }y#
%Paratek Pharmaceuticals, Inc.10Q
11/08/2017Prior InventionsTO:%Paratek Pharmaceuticals, Inc.
FROM:
DATE:
SUBJECT:Prior Inventions$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,}qe!c'=PF0*8X>
@
l N
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??2Boston MA 02116
Balance SheetBalance Sheet (1)Income Statement
Cash FlowsBalance Sheet (2)!3 Cash and Cash Equivalents and7 5 Fixed Assets6 Intangible Assets Net!7 Net Loss Per Share Available !Warrants to Purchase Common Sto10 Other Accrued Expenses11 Fair Value MeasurementsContingent Consideration12 StockBased Compensation12 StockBased C (1)
Stock options16 Restricted Stock Units13 Longterm DebtLeases!Research and Development Expens!Comparison of the three months !Comparison of the nine months e!Liquidity and Capital Resources34 EXHIBIT INDEX34 EXHIBIT INDE (1)35 36 SIGNATURES!Remainder of this page is inten!138 Entire Agreement The obligaPrior Inventions Remainder of this page is (1)138 Entire Agreement The (1)Prior Invention (1)2Due to a prior (1) Remainder of this page is (2)138 Entire Agreement The (2)Prior Invention (2)2Due to a prior (2) Remainder of this page is (3)138 Entire Agreement The (3)Prior Invention (3)2Due to a prior (3) Remainder of this page is (4)138 Entire Agreement The (4)Prior Invention (4)2Due to a prior (4)!SECTION 302 OF THE SARBANESOXLESECTION 302 OF THE (1)!SECTION 906 OF THE SARBANESOXLESECTION 906 OF THE (1)U }$}$ }}$ }}$ }<
%Paratek Pharmaceuticals, Inc.10Q
11/08/2017jb2.Due to a prior confidentiality agreement, I cannot complete the disclosure under Section 1 above Invention or Improvement
Party(ies)Relationship ~
~
~
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,7+=={S=PF0*8X>
@
l Z
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??2Boston MA 02116
Balance SheetBalance Sheet (1)Income Statement
Cash FlowsBalance Sheet (2)!3 Cash and Cash Equivalents and7 5 Fixed Assets6 Intangible Assets Net!7 Net Loss Per Share Available !Warrants to Purchase Common Sto10 Other Accrued Expenses11 Fair Value MeasurementsContingent Consideration12 StockBased Compensation12 StockBased C (1)
Stock options16 Restricted Stock Units13 Longterm DebtLeases!Research and Development Expens!Comparison of the three months !Comparison of the nine months e!Liquidity and Capital Resources34 EXHIBIT INDEX34 EXHIBIT INDE (1)35 36 SIGNATURES!Remainder of this page is inten!138 Entire Agreement The obligaPrior Inventions!2Due to a prior confidentiality138 Entire Agreement The (1)Prior Invention (1)2Due to a prior (1) Remainder of this page is (2)138 Entire Agreement The (2)Prior Invention (2)2Due to a prior (2) Remainder of this page is (3)138 Entire Agreement The (3)Prior Invention (3)2Due to a prior (3) Remainder of this page is (4)138 Entire Agreement The (4)Prior Invention (4)2Due to a prior (4)!SECTION 302 OF THE SARBANESOXLESECTION 302 OF THE (1)!SECTION 906 OF THE SARBANESOXLESECTION 906 OF THE (1)U }1
%Paratek Pharmaceuticals, Inc.10Q
11/08/2017<4[Remainder of this page is intentionally left blank]
Sincerely,
%Paratek Pharmaceuticals, Inc.
/s/ Michael F. BighamMichael F. Bigham1)Chairman of the Board and Chief ExecutiveOfficer Accepted:/s/ William M. HaskelWilliam M. HaskelAugust 4, 2017Date$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/@JDeYMA5kXL7+
w=PF0*8X>
@
l h
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??2Boston MA 02116
Balance SheetBalance Sheet (1)Income Statement
Cash FlowsBalance Sheet (2)!3 Cash and Cash Equivalents and7 5 Fixed Assets6 Intangible Assets Net!7 Net Loss Per Share Available !Warrants to Purchase Common Sto10 Other Accrued Expenses11 Fair Value MeasurementsContingent Consideration12 StockBased Compensation12 StockBased C (1)
Stock options16 Restricted Stock Units13 Longterm DebtLeases!Research and Development Expens!Comparison of the three months !Comparison of the nine months e!Liquidity and Capital Resources34 EXHIBIT INDEX34 EXHIBIT INDE (1)35 36 SIGNATURES!Remainder of this page is inten!138 Entire Agreement The obligaPrior Inventions!2Due to a prior confidentiality Remainder of this page is (1)Prior Invention (1)2Due to a prior (1) Remainder of this page is (2)138 Entire Agreement The (2)Prior Invention (2)2Due to a prior (2) Remainder of this page is (3)138 Entire Agreement The (3)Prior Invention (3)2Due to a prior (3) Remainder of this page is (4)138 Entire Agreement The (4)Prior Invention (4)2Due to a prior (4)!SECTION 302 OF THE SARBANESOXLESECTION 302 OF THE (1)!SECTION 906 OF THE SARBANESOXLESECTION 906 OF THE (1)U }}$ }y
}:
%Paratek Pharmaceuticals, Inc.10Q
11/08/2017kc13.8 Entire Agreement. The obligations pursuant to Sections 1 and 2 (except Subsection 2.6) of this%Paratek Pharmaceuticals, Inc. Name Accepted and agreed:
0(I have read, understand, and Accept this5agreement and have been given the opportunity(Signature)5
to Review it with independent legal counsel .
By:(Signature)Title:
Date:
Date:Address:8075 Park Plaza, 4 th Floor, Boston, Massachusetts~
!$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/66*1xE=PF0*8X>
@Z
l t
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??2Boston MA 02116
Balance SheetBalance Sheet (1)Income Statement
Cash FlowsBalance Sheet (2)!3 Cash and Cash Equivalents and7 5 Fixed Assets6 Intangible Assets Net!7 Net Loss Per Share Available !Warrants to Purchase Common Sto10 Other Accrued Expenses11 Fair Value MeasurementsContingent Consideration12 StockBased Compensation12 StockBased C (1)
Stock options16 Restricted Stock Units13 Longterm DebtLeases!Research and Development Expens!Comparison of the three months !Comparison of the nine months e!Liquidity and Capital Resources34 EXHIBIT INDEX34 EXHIBIT INDE (1)35 36 SIGNATURES!Remainder of this page is inten!138 Entire Agreement The obligaPrior Inventions!2Due to a prior confidentiality Remainder of this page is (1)138 Entire Agreement The (1)2Due to a prior (1) Remainder of this page is (2)138 Entire Agreement The (2)Prior Invention (2)2Due to a prior (2) Remainder of this page is (3)138 Entire Agreement The (3)Prior Invention (3)2Due to a prior (3) Remainder of this page is (4)138 Entire Agreement The (4)Prior Invention (4)2Due to a prior (4)!SECTION 302 OF THE SARBANESOXLESECTION 302 OF THE (1)!SECTION 906 OF THE SARBANESOXLESECTION 906 OF THE (1)U }y
}$ }y#
%Paratek Pharmaceuticals, Inc.10Q
11/08/2017Prior InventionsTO:%Paratek Pharmaceuticals, Inc.
FROM:
DATE:
SUBJECT:Prior Inventions$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,}qe!c'=PF0*8X>
@
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??2Boston MA 02116
Balance SheetBalance Sheet (1)Income Statement
Cash FlowsBalance Sheet (2)!3 Cash and Cash Equivalents and7 5 Fixed Assets6 Intangible Assets Net!7 Net Loss Per Share Available !Warrants to Purchase Common Sto10 Other Accrued Expenses11 Fair Value MeasurementsContingent Consideration12 StockBased Compensation12 StockBased C (1)
Stock options16 Restricted Stock Units13 Longterm DebtLeases!Research and Development Expens!Comparison of the three months !Comparison of the nine months e!Liquidity and Capital Resources34 EXHIBIT INDEX34 EXHIBIT INDE (1)35 36 SIGNATURES!Remainder of this page is inten!138 Entire Agreement The obligaPrior Inventions!2Due to a prior confidentiality Remainder of this page is (1)138 Entire Agreement The (1)Prior Invention (1) Remainder of this page is (2)138 Entire Agreement The (2)Prior Invention (2)2Due to a prior (2) Remainder of this page is (3)138 Entire Agreement The (3)Prior Invention (3)2Due to a prior (3) Remainder of this page is (4)138 Entire Agreement The (4)Prior Invention (4)2Due to a prior (4)!SECTION 302 OF THE SARBANESOXLESECTION 302 OF THE (1)!SECTION 906 OF THE SARBANESOXLESECTION 906 OF THE (1)U }$}$ }}$ }}$ }<
%Paratek Pharmaceuticals, Inc.10Q
11/08/2017jb2.Due to a prior confidentiality agreement, I cannot complete the disclosure under Section 1 above Invention or Improvement
Party(ies)Relationship ~
~
~
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,7+=={S=PF0*8X>
@
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??2Boston MA 02116
Balance SheetBalance Sheet (1)Income Statement
Cash FlowsBalance Sheet (2)!3 Cash and Cash Equivalents and7 5 Fixed Assets6 Intangible Assets Net!7 Net Loss Per Share Available !Warrants to Purchase Common Sto10 Other Accrued Expenses11 Fair Value MeasurementsContingent Consideration12 StockBased Compensation12 StockBased C (1)
Stock options16 Restricted Stock Units13 Longterm DebtLeases!Research and Development Expens!Comparison of the three months !Comparison of the nine months e!Liquidity and Capital Resources34 EXHIBIT INDEX34 EXHIBIT INDE (1)35 36 SIGNATURES!Remainder of this page is inten!138 Entire Agreement The obligaPrior Inventions!2Due to a prior confidentiality Remainder of this page is (1)138 Entire Agreement The (1)Prior Invention (1)2Due to a prior (1)138 Entire Agreement The (2)Prior Invention (2)2Due to a prior (2) Remainder of this page is (3)138 Entire Agreement The (3)Prior Invention (3)2Due to a prior (3) Remainder of this page is (4)138 Entire Agreement The (4)Prior Invention (4)2Due to a prior (4)!SECTION 302 OF THE SARBANESOXLESECTION 302 OF THE (1)!SECTION 906 OF THE SARBANESOXLESECTION 906 OF THE (1)U }y#}$
%Paratek Pharmaceuticals, Inc.10Q
11/08/2017<4[Remainder of this page is intentionally left blank]
Sincerely, %
Paratek Pharmaceuticals, Inc.
/s/ Michael F. Bigham
Michael F. Bigham
1)Chairman of the Board and Chief ExecutiveOfficer Accepted:/s/ Evan Loh, M.D.Evan Loh, M.D.August 4, 2017Date$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/>0eYMAQwSmaU=PF0*8X>
@*
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??2Boston MA 02116
Balance SheetBalance Sheet (1)Income Statement
Cash FlowsBalance Sheet (2)!3 Cash and Cash Equivalents and7 5 Fixed Assets6 Intangible Assets Net!7 Net Loss Per Share Available !Warrants to Purchase Common Sto10 Other Accrued Expenses11 Fair Value MeasurementsContingent Consideration12 StockBased Compensation12 StockBased C (1)
Stock options16 Restricted Stock Units13 Longterm DebtLeases!Research and Development Expens!Comparison of the three months !Comparison of the nine months e!Liquidity and Capital Resources34 EXHIBIT INDEX34 EXHIBIT INDE (1)35 36 SIGNATURES!Remainder of this page is inten!138 Entire Agreement The obligaPrior Inventions!2Due to a prior confidentiality Remainder of this page is (1)138 Entire Agreement The (1)Prior Invention (1)2Due to a prior (1) Remainder of this page is (2)Prior Invention (2)2Due to a prior (2) Remainder of this page is (3)138 Entire Agreement The (3)Prior Invention (3)2Due to a prior (3) Remainder of this page is (4)138 Entire Agreement The (4)Prior Invention (4)2Due to a prior (4)!SECTION 302 OF THE SARBANESOXLESECTION 302 OF THE (1)!SECTION 906 OF THE SARBANESOXLESECTION 906 OF THE (1)U }$ }}$ }}$ }
%Paratek Pharmaceuticals, Inc.10Q
11/08/2017kc13.8 Entire Agreement. The obligations pursuant to Sections 1 and 2 (except Subsection 2.6) of this :%Paratek Pharmaceuticals, Inc. Name Accepted and agreed:
0(I have read, understand, and Accept this(Signature)5
agreement and have been given the opportunity5to Review it with independent legal counsel .By:Title:(Signature)
Date:
Date:3+Address: 75 Park Plaza, 4 th Floor, Boston,Massachusetts 02116$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/:6*L\Zm=PF0*8X>
@j
l p
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??2Boston MA 02116
Balance SheetBalance Sheet (1)Income Statement
Cash FlowsBalance Sheet (2)!3 Cash and Cash Equivalents and7 5 Fixed Assets6 Intangible Assets Net!7 Net Loss Per Share Available !Warrants to Purchase Common Sto10 Other Accrued Expenses11 Fair Value MeasurementsContingent Consideration12 StockBased Compensation12 StockBased C (1)
Stock options16 Restricted Stock Units13 Longterm DebtLeases!Research and Development Expens!Comparison of the three months !Comparison of the nine months e!Liquidity and Capital Resources34 EXHIBIT INDEX34 EXHIBIT INDE (1)35 36 SIGNATURES!Remainder of this page is inten!138 Entire Agreement The obligaPrior Inventions!2Due to a prior confidentiality Remainder of this page is (1)138 Entire Agreement The (1)Prior Invention (1)2Due to a prior (1) Remainder of this page is (2)138 Entire Agreement The (2)2Due to a prior (2) Remainder of this page is (3)138 Entire Agreement The (3)Prior Invention (3)2Due to a prior (3) Remainder of this page is (4)138 Entire Agreement The (4)Prior Invention (4)2Due to a prior (4)!SECTION 302 OF THE SARBANESOXLESECTION 302 OF THE (1)!SECTION 906 OF THE SARBANESOXLESECTION 906 OF THE (1)U }}$ }y#}$
%Paratek Pharmaceuticals, Inc.10Q
11/08/2017Prior InventionsTO:%Paratek Pharmaceuticals, Inc.
FROM:
DATE:
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/(T}qeK?3=PF0*8X>
@
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??2Boston MA 02116
Balance SheetBalance Sheet (1)Income Statement
Cash FlowsBalance Sheet (2)!3 Cash and Cash Equivalents and7 5 Fixed Assets6 Intangible Assets Net!7 Net Loss Per Share Available !Warrants to Purchase Common Sto10 Other Accrued Expenses11 Fair Value MeasurementsContingent Consideration12 StockBased Compensation12 StockBased C (1)
Stock options16 Restricted Stock Units13 Longterm DebtLeases!Research and Development Expens!Comparison of the three months !Comparison of the nine months e!Liquidity and Capital Resources34 EXHIBIT INDEX34 EXHIBIT INDE (1)35 36 SIGNATURES!Remainder of this page is inten!138 Entire Agreement The obligaPrior Inventions!2Due to a prior confidentiality Remainder of this page is (1)138 Entire Agreement The (1)Prior Invention (1)2Due to a prior (1) Remainder of this page is (2)138 Entire Agreement The (2)Prior Invention (2) Remainder of this page is (3)138 Entire Agreement The (3)Prior Invention (3)2Due to a prior (3) Remainder of this page is (4)138 Entire Agreement The (4)Prior Invention (4)2Due to a prior (4)!SECTION 302 OF THE SARBANESOXLESECTION 302 OF THE (1)!SECTION 906 OF THE SARBANESOXLESECTION 906 OF THE (1)U }$}}$ }}$ }<
%Paratek Pharmaceuticals, Inc.10Q
11/08/2017jb2.Due to a prior confidentiality agreement, I cannot complete the disclosure under Section 1 above Invention or Improvement
Party(ies)Relationship ~
~
~
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/0
7+Uy1WK?=PF0*8X>
@
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??2Boston MA 02116
Balance SheetBalance Sheet (1)Income Statement
Cash FlowsBalance Sheet (2)!3 Cash and Cash Equivalents and7 5 Fixed Assets6 Intangible Assets Net!7 Net Loss Per Share Available !Warrants to Purchase Common Sto10 Other Accrued Expenses11 Fair Value MeasurementsContingent Consideration12 StockBased Compensation12 StockBased C (1)
Stock options16 Restricted Stock Units13 Longterm DebtLeases!Research and Development Expens!Comparison of the three months !Comparison of the nine months e!Liquidity and Capital Resources34 EXHIBIT INDEX34 EXHIBIT INDE (1)35 36 SIGNATURES!Remainder of this page is inten!138 Entire Agreement The obligaPrior Inventions!2Due to a prior confidentiality Remainder of this page is (1)138 Entire Agreement The (1)Prior Invention (1)2Due to a prior (1) Remainder of this page is (2)138 Entire Agreement The (2)Prior Invention (2)2Due to a prior (2)138 Entire Agreement The (3)Prior Invention (3)2Due to a prior (3) Remainder of this page is (4)138 Entire Agreement The (4)Prior Invention (4)2Due to a prior (4)!SECTION 302 OF THE SARBANESOXLESECTION 302 OF THE (1)!SECTION 906 OF THE SARBANESOXLESECTION 906 OF THE (1)U }1
%Paratek Pharmaceuticals, Inc.10Q
11/08/2017<4[Remainder of this page is intentionally left blank]
Sincerely,
%Paratek Pharmaceuticals, Inc.
/s/ Michael F. BighamMichael F. Bigham1)Chairman of the Board and Chief ExecutiveOfficer Accepted:/s/ Douglas Pag?n
Douglas Pag?nAugust 4, 2017Date$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/@BDeYMA5kXL7+=PF0*8X>
@
l 0
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??2Boston MA 02116
Balance SheetBalance Sheet (1)Income Statement
Cash FlowsBalance Sheet (2)!3 Cash and Cash Equivalents and7 5 Fixed Assets6 Intangible Assets Net!7 Net Loss Per Share Available !Warrants to Purchase Common Sto10 Other Accrued Expenses11 Fair Value MeasurementsContingent Consideration12 StockBased Compensation12 StockBased C (1)
Stock options16 Restricted Stock Units13 Longterm DebtLeases!Research and Development Expens!Comparison of the three months !Comparison of the nine months e!Liquidity and Capital Resources34 EXHIBIT INDEX34 EXHIBIT INDE (1)35 36 SIGNATURES!Remainder of this page is inten!138 Entire Agreement The obligaPrior Inventions!2Due to a prior confidentiality Remainder of this page is (1)138 Entire Agreement The (1)Prior Invention (1)2Due to a prior (1) Remainder of this page is (2)138 Entire Agreement The (2)Prior Invention (2)2Due to a prior (2) Remainder of this page is (3)Prior Invention (3)2Due to a prior (3) Remainder of this page is (4)138 Entire Agreement The (4)Prior Invention (4)2Due to a prior (4)!SECTION 302 OF THE SARBANESOXLESECTION 302 OF THE (1)!SECTION 906 OF THE SARBANESOXLESECTION 906 OF THE (1)U }}$ }y
}:
%Paratek Pharmaceuticals, Inc.10Q
11/08/2017kc13.8 Entire Agreement. The obligations pursuant to Sections 1 and 2 (except Subsection 2.6) of this%Paratek Pharmaceuticals, Inc. Name Accepted and agreed:
0(I have read, understand, and Accept this5agreement and have been given the opportunity(Signature)5
to Review it with independent legal counsel .
By:(Signature)Title:
Date:
Date:Address:8075 Park Plaza, 4 th Floor, Boston, Massachusetts~
! :$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/86*1xEk=PF0*8X>
@Z
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??2Boston MA 02116
Balance SheetBalance Sheet (1)Income Statement
Cash FlowsBalance Sheet (2)!3 Cash and Cash Equivalents and7 5 Fixed Assets6 Intangible Assets Net!7 Net Loss Per Share Available !Warrants to Purchase Common Sto10 Other Accrued Expenses11 Fair Value MeasurementsContingent Consideration12 StockBased Compensation12 StockBased C (1)
Stock options16 Restricted Stock Units13 Longterm DebtLeases!Research and Development Expens!Comparison of the three months !Comparison of the nine months e!Liquidity and Capital Resources34 EXHIBIT INDEX34 EXHIBIT INDE (1)35 36 SIGNATURES!Remainder of this page is inten!138 Entire Agreement The obligaPrior Inventions!2Due to a prior confidentiality Remainder of this page is (1)138 Entire Agreement The (1)Prior Invention (1)2Due to a prior (1) Remainder of this page is (2)138 Entire Agreement The (2)Prior Invention (2)2Due to a prior (2) Remainder of this page is (3)138 Entire Agreement The (3)2Due to a prior (3) Remainder of this page is (4)138 Entire Agreement The (4)Prior Invention (4)2Due to a prior (4)!SECTION 302 OF THE SARBANESOXLESECTION 302 OF THE (1)!SECTION 906 OF THE SARBANESOXLESECTION 906 OF THE (1)U }y
}$ }y#
%Paratek Pharmaceuticals, Inc.10Q
11/08/2017Prior InventionsTO:%Paratek Pharmaceuticals, Inc.
FROM:
DATE:
SUBJECT:Prior Inventions$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,}qe!c'=PF0*8X>
@
l g
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??2Boston MA 02116
Balance SheetBalance Sheet (1)Income Statement
Cash FlowsBalance Sheet (2)!3 Cash and Cash Equivalents and7 5 Fixed Assets6 Intangible Assets Net!7 Net Loss Per Share Available !Warrants to Purchase Common Sto10 Other Accrued Expenses11 Fair Value MeasurementsContingent Consideration12 StockBased Compensation12 StockBased C (1)
Stock options16 Restricted Stock Units13 Longterm DebtLeases!Research and Development Expens!Comparison of the three months !Comparison of the nine months e!Liquidity and Capital Resources34 EXHIBIT INDEX34 EXHIBIT INDE (1)35 36 SIGNATURES!Remainder of this page is inten!138 Entire Agreement The obligaPrior Inventions!2Due to a prior confidentiality Remainder of this page is (1)138 Entire Agreement The (1)Prior Invention (1)2Due to a prior (1) Remainder of this page is (2)138 Entire Agreement The (2)Prior Invention (2)2Due to a prior (2) Remainder of this page is (3)138 Entire Agreement The (3)Prior Invention (3) Remainder of this page is (4)138 Entire Agreement The (4)Prior Invention (4)2Due to a prior (4)!SECTION 302 OF THE SARBANESOXLESECTION 302 OF THE (1)!SECTION 906 OF THE SARBANESOXLESECTION 906 OF THE (1)U }$}$ }}$ }}$ }<
%Paratek Pharmaceuticals, Inc.10Q
11/08/2017jb2.Due to a prior confidentiality agreement, I cannot complete the disclosure under Section 1 above Invention or Improvement
Party(ies)Relationship ~
~
~
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,7+=={S=PF0*8X>
@
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??2Boston MA 02116
Balance SheetBalance Sheet (1)Income Statement
Cash FlowsBalance Sheet (2)!3 Cash and Cash Equivalents and7 5 Fixed Assets6 Intangible Assets Net!7 Net Loss Per Share Available !Warrants to Purchase Common Sto10 Other Accrued Expenses11 Fair Value MeasurementsContingent Consideration12 StockBased Compensation12 StockBased C (1)
Stock options16 Restricted Stock Units13 Longterm DebtLeases!Research and Development Expens!Comparison of the three months !Comparison of the nine months e!Liquidity and Capital Resources34 EXHIBIT INDEX34 EXHIBIT INDE (1)35 36 SIGNATURES!Remainder of this page is inten!138 Entire Agreement The obligaPrior Inventions!2Due to a prior confidentiality Remainder of this page is (1)138 Entire Agreement The (1)Prior Invention (1)2Due to a prior (1) Remainder of this page is (2)138 Entire Agreement The (2)Prior Invention (2)2Due to a prior (2) Remainder of this page is (3)138 Entire Agreement The (3)Prior Invention (3)2Due to a prior (3)138 Entire Agreement The (4)Prior Invention (4)2Due to a prior (4)!SECTION 302 OF THE SARBANESOXLESECTION 302 OF THE (1)!SECTION 906 OF THE SARBANESOXLESECTION 906 OF THE (1)U }1
%Paratek Pharmaceuticals, Inc.10Q
11/08/2017<4[Remainder of this page is intentionally left blank]
Sincerely,
%Paratek Pharmaceuticals, Inc.
/s/ Michael F. BighamMichael F. Bigham1)Chairman of the Board and Chief ExecutiveOfficer Accepted:/s/ Adam WoodrowAdam WoodrowAugust 4, 2017Date$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/@@DeYMA5kXL7+=PF0*8X>
@
l 
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??2Boston MA 02116
Balance SheetBalance Sheet (1)Income Statement
Cash FlowsBalance Sheet (2)!3 Cash and Cash Equivalents and7 5 Fixed Assets6 Intangible Assets Net!7 Net Loss Per Share Available !Warrants to Purchase Common Sto10 Other Accrued Expenses11 Fair Value MeasurementsContingent Consideration12 StockBased Compensation12 StockBased C (1)
Stock options16 Restricted Stock Units13 Longterm DebtLeases!Research and Development Expens!Comparison of the three months !Comparison of the nine months e!Liquidity and Capital Resources34 EXHIBIT INDEX34 EXHIBIT INDE (1)35 36 SIGNATURES!Remainder of this page is inten!138 Entire Agreement The obligaPrior Inventions!2Due to a prior confidentiality Remainder of this page is (1)138 Entire Agreement The (1)Prior Invention (1)2Due to a prior (1) Remainder of this page is (2)138 Entire Agreement The (2)Prior Invention (2)2Due to a prior (2) Remainder of this page is (3)138 Entire Agreement The (3)Prior Invention (3)2Due to a prior (3) Remainder of this page is (4)Prior Invention (4)2Due to a prior (4)!SECTION 302 OF THE SARBANESOXLESECTION 302 OF THE (1)!SECTION 906 OF THE SARBANESOXLESECTION 906 OF THE (1)U }}$ }y
}:
%Paratek Pharmaceuticals, Inc.10Q
11/08/2017kc13.8 Entire Agreement. The obligations pursuant to Sections 1 and 2 (except Subsection 2.6) of this%Paratek Pharmaceuticals, Inc. Name Accepted and agreed:
0(I have read, understand, and Accept this5agreement and have been given the opportunity(Signature)5
to Review it with independent legal counsel .
By:(Signature)Title:
Date:
Date:Address:8075 Park Plaza, 4 th Floor, Boston, Massachusetts~
!$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/66*1xE=PF0*8X>
@Z
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??2Boston MA 02116
Balance SheetBalance Sheet (1)Income Statement
Cash FlowsBalance Sheet (2)!3 Cash and Cash Equivalents and7 5 Fixed Assets6 Intangible Assets Net!7 Net Loss Per Share Available !Warrants to Purchase Common Sto10 Other Accrued Expenses11 Fair Value MeasurementsContingent Consideration12 StockBased Compensation12 StockBased C (1)
Stock options16 Restricted Stock Units13 Longterm DebtLeases!Research and Development Expens!Comparison of the three months !Comparison of the nine months e!Liquidity and Capital Resources34 EXHIBIT INDEX34 EXHIBIT INDE (1)35 36 SIGNATURES!Remainder of this page is inten!138 Entire Agreement The obligaPrior Inventions!2Due to a prior confidentiality Remainder of this page is (1)138 Entire Agreement The (1)Prior Invention (1)2Due to a prior (1) Remainder of this page is (2)138 Entire Agreement The (2)Prior Invention (2)2Due to a prior (2) Remainder of this page is (3)138 Entire Agreement The (3)Prior Invention (3)2Due to a prior (3) Remainder of this page is (4)138 Entire Agreement The (4)2Due to a prior (4)!SECTION 302 OF THE SARBANESOXLESECTION 302 OF THE (1)!SECTION 906 OF THE SARBANESOXLESECTION 906 OF THE (1)U }y
}$ }y#
%Paratek Pharmaceuticals, Inc.10Q
11/08/2017Prior InventionsTO:%Paratek Pharmaceuticals, Inc.
FROM:
DATE:
SUBJECT:Prior Inventions$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,}qe!c'=PF0*8X>
@
l b!
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??2Boston MA 02116
Balance SheetBalance Sheet (1)Income Statement
Cash FlowsBalance Sheet (2)!3 Cash and Cash Equivalents and7 5 Fixed Assets6 Intangible Assets Net!7 Net Loss Per Share Available !Warrants to Purchase Common Sto10 Other Accrued Expenses11 Fair Value MeasurementsContingent Consideration12 StockBased Compensation12 StockBased C (1)
Stock options16 Restricted Stock Units13 Longterm DebtLeases!Research and Development Expens!Comparison of the three months !Comparison of the nine months e!Liquidity and Capital Resources34 EXHIBIT INDEX34 EXHIBIT INDE (1)35 36 SIGNATURES!Remainder of this page is inten!138 Entire Agreement The obligaPrior Inventions!2Due to a prior confidentiality Remainder of this page is (1)138 Entire Agreement The (1)Prior Invention (1)2Due to a prior (1) Remainder of this page is (2)138 Entire Agreement The (2)Prior Invention (2)2Due to a prior (2) Remainder of this page is (3)138 Entire Agreement The (3)Prior Invention (3)2Due to a prior (3) Remainder of this page is (4)138 Entire Agreement The (4)Prior Invention (4)!SECTION 302 OF THE SARBANESOXLESECTION 302 OF THE (1)!SECTION 906 OF THE SARBANESOXLESECTION 906 OF THE (1)U }$}$ }}$ }}$ }<
%Paratek Pharmaceuticals, Inc.10Q
11/08/2017jb2.Due to a prior confidentiality agreement, I cannot complete the disclosure under Section 1 above Invention or Improvement
Party(ies)Relationship ~
~
~
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,7+=={S=PF0*8X>
@
l B,
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??2Boston MA 02116
Balance SheetBalance Sheet (1)Income Statement
Cash FlowsBalance Sheet (2)!3 Cash and Cash Equivalents and7 5 Fixed Assets6 Intangible Assets Net!7 Net Loss Per Share Available !Warrants to Purchase Common Sto10 Other Accrued Expenses11 Fair Value MeasurementsContingent Consideration12 StockBased Compensation12 StockBased C (1)
Stock options16 Restricted Stock Units13 Longterm DebtLeases!Research and Development Expens!Comparison of the three months !Comparison of the nine months e!Liquidity and Capital Resources34 EXHIBIT INDEX34 EXHIBIT INDE (1)35 36 SIGNATURES!Remainder of this page is inten!138 Entire Agreement The obligaPrior Inventions!2Due to a prior confidentiality Remainder of this page is (1)138 Entire Agreement The (1)Prior Invention (1)2Due to a prior (1) Remainder of this page is (2)138 Entire Agreement The (2)Prior Invention (2)2Due to a prior (2) Remainder of this page is (3)138 Entire Agreement The (3)Prior Invention (3)2Due to a prior (3) Remainder of this page is (4)138 Entire Agreement The (4)Prior Invention (4)2Due to a prior (4)SECTION 302 OF THE (1)!SECTION 906 OF THE SARBANESOXLESECTION 906 OF THE (1)U }1
%Paratek Pharmaceuticals, Inc.10Q
11/08/20175SECTION 302 OF THE SARBANESOXLEY ACT OF 2002
/s/ MICHAEL F. BIGHAMMichael F. Bigham
Chief Executive OfficerNovember 7, 2017$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,l`TH<0g=PF0*8X>
@
l
7
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??2Boston MA 02116
Balance SheetBalance Sheet (1)Income Statement
Cash FlowsBalance Sheet (2)!3 Cash and Cash Equivalents and7 5 Fixed Assets6 Intangible Assets Net!7 Net Loss Per Share Available !Warrants to Purchase Common Sto10 Other Accrued Expenses11 Fair Value MeasurementsContingent Consideration12 StockBased Compensation12 StockBased C (1)
Stock options16 Restricted Stock Units13 Longterm DebtLeases!Research and Development Expens!Comparison of the three months !Comparison of the nine months e!Liquidity and Capital Resources34 EXHIBIT INDEX34 EXHIBIT INDE (1)35 36 SIGNATURES!Remainder of this page is inten!138 Entire Agreement The obligaPrior Inventions!2Due to a prior confidentiality Remainder of this page is (1)138 Entire Agreement The (1)Prior Invention (1)2Due to a prior (1) Remainder of this page is (2)138 Entire Agreement The (2)Prior Invention (2)2Due to a prior (2) Remainder of this page is (3)138 Entire Agreement The (3)Prior Invention (3)2Due to a prior (3) Remainder of this page is (4)138 Entire Agreement The (4)Prior Invention (4)2Due to a prior (4)!SECTION 302 OF THE SARBANESOXLE!SECTION 906 OF THE SARBANESOXLESECTION 906 OF THE (1)U }1
%Paratek Pharmaceuticals, Inc.10Q
11/08/20175SECTION 302 OF THE SARBANESOXLEY ACT OF 2002
/s/ DOUGLAS W. PAGANDouglas W. Pag?n
Chief Financial OfficerNovember 7, 2017$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,l`TH<0i=PF0*8X>
@
l \A
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??2Boston MA 02116
Balance SheetBalance Sheet (1)Income Statement
Cash FlowsBalance Sheet (2)!3 Cash and Cash Equivalents and7 5 Fixed Assets6 Intangible Assets Net!7 Net Loss Per Share Available !Warrants to Purchase Common Sto10 Other Accrued Expenses11 Fair Value MeasurementsContingent Consideration12 StockBased Compensation12 StockBased C (1)
Stock options16 Restricted Stock Units13 Longterm DebtLeases!Research and Development Expens!Comparison of the three months !Comparison of the nine months e!Liquidity and Capital Resources34 EXHIBIT INDEX34 EXHIBIT INDE (1)35 36 SIGNATURES!Remainder of this page is inten!138 Entire Agreement The obligaPrior Inventions!2Due to a prior confidentiality Remainder of this page is (1)138 Entire Agreement The (1)Prior Invention (1)2Due to a prior (1) Remainder of this page is (2)138 Entire Agreement The (2)Prior Invention (2)2Due to a prior (2) Remainder of this page is (3)138 Entire Agreement The (3)Prior Invention (3)2Due to a prior (3) Remainder of this page is (4)138 Entire Agreement The (4)Prior Invention (4)2Due to a prior (4)!SECTION 302 OF THE SARBANESOXLESECTION 302 OF THE (1)SECTION 906 OF THE (1)U }1
%Paratek Pharmaceuticals, Inc.10Q
11/08/20175SECTION 906 OF THE SARBANESOXLEY ACT OF 2002/s/ MICHAEL F. BIGHAM
Michael F. BighamChief Executive Officer
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/&"@l`TH'=PF0*8X>
@
l K
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??2Boston MA 02116
Balance SheetBalance Sheet (1)Income Statement
Cash FlowsBalance Sheet (2)!3 Cash and Cash Equivalents and7 5 Fixed Assets6 Intangible Assets Net!7 Net Loss Per Share Available !Warrants to Purchase Common Sto10 Other Accrued Expenses11 Fair Value MeasurementsContingent Consideration12 StockBased Compensation12 StockBased C (1)
Stock options16 Restricted Stock Units13 Longterm DebtLeases!Research and Development Expens!Comparison of the three months !Comparison of the nine months e!Liquidity and Capital Resources34 EXHIBIT INDEX34 EXHIBIT INDE (1)35 36 SIGNATURES!Remainder of this page is inten!138 Entire Agreement The obligaPrior Inventions!2Due to a prior confidentiality Remainder of this page is (1)138 Entire Agreement The (1)Prior Invention (1)2Due to a prior (1) Remainder of this page is (2)138 Entire Agreement The (2)Prior Invention (2)2Due to a prior (2) Remainder of this page is (3)138 Entire Agreement The (3)Prior Invention (3)2Due to a prior (3) Remainder of this page is (4)138 Entire Agreement The (4)Prior Invention (4)2Due to a prior (4)!SECTION 302 OF THE SARBANESOXLESECTION 302 OF THE (1)!SECTION 906 OF THE SARBANESOXLEU }1
%Paratek Pharmaceuticals, Inc.10Q
11/08/20175SECTION 906 OF THE SARBANESOXLEY ACT OF 2002/s/ DOUGLAS W. PAG?N
Douglas W. Pag?nChief Financial Officer
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/& @l`TH(=PF0*8X>
@
Root Entry FBook
L
!"#$%&'()*+,./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{}~
!"#$%&'()*+,./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{}~